

1. Name of the medicinal product

Wegovy® 0.25 mg/dose FlexTouch® solution for injection in pre-filled pen (0.68 mg/mL)

Wegovy® 0.5 mg/dose FlexTouch® solution for injection in pre-filled pen (1.34 mg/mL)

Wegovy® 1 mg/dose FlexTouch® solution for injection in pre-filled pen (1.34 mg/mL)

Wegovy® 1.7 mg/dose FlexTouch® solution for injection in pre-filled pen (2.27 mg/mL)

Wegovy® 2.4 mg/dose FlexTouch® solution for injection in pre-filled pen (3.2 mg/mL)

2. Qualitative and quantitative composition

Wegovy® 0.25 mg/dose FlexTouch® solution for injection pre-filled pen (0.68 mg/mL)

Each pre-filled pen contains 1 mg semaglutide* in 1.5 mL solution. One mL of solution contains 0.68 mg semaglutide*. One pre-filled pen contains 4 doses of 0.25 mg.

Wegovy® 0.5 mg/dose FlexTouch® solution for injection pre-filled pen (1.34 mg/mL)

Each pre-filled pen contains 2 mg semaglutide* in 1.5 mL solution. One mL of solution contains 1.34 mg semaglutide*. One pre-filled pen contains 4 doses of 0.5 mg.

Wegovy® 1 mg/dose FlexTouch® solution for injection pre-filled pen (1.34 mg/mL)

Each pre-filled pen contains 4 mg semaglutide* in 3 mL solution. One mL of solution contains 1.34 mg semaglutide*. One pre-filled pen contains 4 doses of 1 mg.

Wegovy® 1.7 mg/dose FlexTouch® solution for injection pre-filled pen (2.27 mg/mL)

Each pre-filled pen contains 6.8 mg semaglutide* in 3 mL solution. One mL of solution contains 2.27 mg semaglutide*. One pre-filled pen contains 4 doses of 1.7 mg.

Wegovy® 2.4 mg/dose FlexTouch® solution for injection pre-filled pen (3.2 mg/mL)

Each pre-filled pen contains 9.6 mg semaglutide* in 3 mL solution. One mL of solution contains 3.2 mg semaglutide*. One pre-filled pen contains 4 doses of 2.4 mg.

*human glucagon-like peptide-1 (GLP-1) analogue produced in *Saccharomyces cerevisiae* cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Solution for injection

Clear and colourless or almost colourless, isotonic solution; pH=7.4.

4. Clinical particulars

4.1 Therapeutic indications

Adults

Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity:

- For weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of
 - ≥ 30 kg/m² (obesity), or
 - ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

- To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.

For trial results with respect to cardiovascular risk reduction, obesity-related heart failure, and populations studied, see section 5.1.

Adolescents (≥12 years)

Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with

- obesity* and
- body weight above 60 kg.

Treatment with Wegovy® should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.

*Obesity (BMI ≥95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).

Table 1 BMI cut-off points for obesity (≥95th percentile) by sex and age for paediatric patients aged 12 and older (CDC criteria)

Age (years)	BMI (kg/m ²) at 95 th Percentile	
	Males	Females
12	24.2	25.2
12.5	24.7	25.7
13	25.1	26.3
13.5	25.6	26.8
14	26.0	27.2
14.5	26.4	27.7
15	26.8	28.1
15.5	27.2	28.5
16	27.5	28.9
16.5	27.9	29.3
17	28.2	29.6
17.5	28.6	30.0

Limitation of Use

Wegovy® contains semaglutide and should not be co-administered with other semaglutide containing products or with any other GLP-1 receptor agonist.

The safety and effectiveness of Wegovy® in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.

Wegovy® has not been studied in patients with a history of pancreatitis (see section 4.4).

Adolescents (≥12 years)

The safety and efficacy of semaglutide in prepubertal adolescents (Tanner stage 1) have not

been established.

4.2 Posology and method of administration

Posology

Adults

The maintenance dose of semaglutide 2.4 mg once-weekly is reached by starting with a dose of 0.25 mg. To reduce the likelihood of gastrointestinal symptoms, the dose should be escalated over a 16-week period to a maintenance dose of 2.4 mg once weekly (see Table 2). In case of significant gastrointestinal symptoms, consider delaying dose escalation or lowering to the previous dose until symptoms have improved. Weekly doses higher than 2.4 mg are not recommended.

Table 2 Dose escalation schedule

Dose escalation	Weekly dose
Week 1 – 4	0.25 mg
Week 5 – 8	0.5 mg
Week 9 – 12	1 mg
Week 13 – 16	1.7 mg
Maintenance dose	2.4 mg

Adolescents

For adolescents ages 12 years and above, the same dose escalation schedule as for adults should be applied (see Table 2). The dose should be increased until 2.4 mg (maintenance dose) or maximum tolerated dose has been reached. Weekly doses higher than 2.4 mg are not recommended.

Patients with type 2 diabetes

When initiating semaglutide in patients with type 2 diabetes, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (such as sulfonylureas) to reduce the risk of hypoglycaemia, see section 4.4.

Clinical data on efficacy and safety are limited to 68 weeks.

Missed dose

If a dose is missed, it should be administered as soon as possible and within 5 days after the missed dose. If more than 5 days have passed, the missed dose should be skipped, and the next dose should be administered on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule. If more doses are missed, reducing the starting dose for re-initiation should be considered.

Special populations

Elderly (≥65 years old)

No dose adjustment is required based on age. Therapeutic experience in patients ≥85 years of age is limited.

Patients with renal impairment

No dose adjustment is required for patients with mild or moderate renal impairment.

Experience with the use of semaglutide in patients with severe renal impairment is limited. Semaglutide is not recommended for use in patients with severe renal impairment (eGFR <30 mL/min/1.73m²) including patients with end-stage renal disease (see sections 4.4, 4.8 and 5.2).

Patients with hepatic impairment

No dose adjustment is required for patients with mild or moderate hepatic impairment. Experience with the use of semaglutide in patients with severe hepatic impairment is limited. Semaglutide is not recommended for use in patients with severe hepatic impairment and should be used cautiously in patients with mild or moderate hepatic impairment (see sections 4.4 and 5.2).

Paediatric population

No dose adjustment is required for adolescents ages 12 years and above. The safety and efficacy of semaglutide in children below 12 years of age and prepubertal adolescent have not been established.

Method of administration

Subcutaneous use.

Wegovy® is administered once weekly at any time of the day, with or without meals.

It is to be injected subcutaneously in the abdomen, in the thigh or in the upper arm. The injection site can be changed. It should not be administered intravenously or intramuscularly.

The day of weekly administration can be changed if necessary, as long as the time between two doses is at least 3 days (>72 hours). After selecting a new dosing day, once-weekly dosing should be continued.

Patients should be advised to read the instruction for use included in the package leaflet carefully before administering the medicinal product.

For further information before administration see section 6.6.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Aspiration in association with general anaesthesia or deep sedation

Cases of pulmonary aspiration have been reported in patients receiving GLP-1 receptor agonists undergoing general anaesthesia or deep sedation. Therefore, the increased risk of residual gastric content due to delayed gastric emptying (see section 4.8) should be considered prior to performing procedures with general anaesthesia or deep sedation.

Dehydration

Use of GLP-1 receptor agonists may be associated with gastrointestinal adverse reactions that can cause dehydration, which in rare cases can lead to a deterioration of renal function. Patients should be advised of the potential risk of dehydration in relation to gastrointestinal side effects and take precautions to avoid fluid depletion.

Acute pancreatitis

Acute pancreatitis has been observed with the use of GLP-1 receptor agonists (see section 4.8). Patients should be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, semaglutide should be discontinued; if confirmed, semaglutide should not be restarted. Caution should be exercised in patients with a history of pancreatitis.

In the absence of other signs and symptoms of acute pancreatitis, elevations in pancreatic enzymes alone are not predictive of acute pancreatitis.

Patients with type 2 diabetes

Semaglutide should not be used as a substitute for insulin in patients with type 2 diabetes.

Semaglutide should not be used in combination with other GLP-1 receptor agonist products. It has not been evaluated and an increased risk of adverse reactions related to overdose is considered likely.

Hypoglycaemia in patients with type 2 diabetes

Insulin and sulfonylurea are known to cause hypoglycaemia. Patients treated with semaglutide in combination with a sulfonylurea or insulin may have an increased risk of hypoglycaemia. The risk of hypoglycaemia can be lowered by reducing the dose of sulfonylurea or insulin when initiating treatment with a GLP-1 receptor agonist.

Diabetic retinopathy in patients with type 2 diabetes

In patients with diabetic retinopathy treated with semaglutide, an increased risk of developing diabetic retinopathy complications has been observed (see section 4.8). Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy, but other mechanisms cannot be excluded. Patients with diabetic retinopathy using semaglutide should be monitored closely and treated according to clinical guidelines. There is no experience with Wegovy® in patients with type 2 diabetes with uncontrolled or potentially unstable diabetic retinopathy. In these patients, treatment with Wegovy® is not recommended.

Populations not studied

The safety and efficacy of Wegovy® have not been investigated in patients:

- treated with other products for weight management,
- with type 1 diabetes,
- with severe renal impairment (see section 4.2),
- with severe hepatic impairment (see section 4.2),
- with congestive heart failure New York Heart Association (NYHA) class IV.

Use in these patients is not recommended.

There is limited experience with Wegovy® in patients:

- aged 85 years or more (see section 4.2),
- with mild or moderate hepatic impairment (see section 4.2),
- with inflammatory bowel disease,
- with diabetic gastroparesis.

Use with caution in these patients.

Sodium content

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.

4.5 Interaction with other medicinal products and other forms of interaction

Semaglutide delays gastric emptying and could potentially influence the absorption of concomitantly administered oral medicinal products. No clinically relevant effect on the rate of gastric emptying was observed with semaglutide 2.4 mg, probably due to a tolerance effect. Semaglutide should be used with caution in patients receiving oral medicinal products that require rapid gastrointestinal absorption.

Paracetamol

Semaglutide delays the rate of gastric emptying as assessed by paracetamol pharmacokinetics during a standardised meal test. Paracetamol $AUC_{0-60min}$ and C_{max} were decreased by 27% and 23%, respectively, following concomitant use of semaglutide 1 mg. The total paracetamol exposure (AUC_{0-5h}) was not affected. No clinically relevant effect on paracetamol was observed with semaglutide. No dose adjustment of paracetamol is necessary when administered with semaglutide.

Oral contraceptives

Semaglutide is not anticipated to decrease the effectiveness of oral contraceptives. It did not change the overall exposure of ethinylestradiol and levonorgestrel to a clinically relevant degree, when an oral contraceptive combination medicinal product (0.03 mg ethinylestradiol/0.15 mg levonorgestrel) was co-administered with semaglutide. Exposure of ethinylestradiol was not affected; an increase of 20% was observed for levonorgestrel exposure at steady state. C_{max} was not affected for any of the compounds.

Atorvastatin

Semaglutide did not change the overall exposure of atorvastatin following a single dose administration of atorvastatin (40 mg). Atorvastatin C_{max} was decreased by 38%. This was assessed not to be clinically relevant.

Digoxin

Semaglutide did not change the overall exposure or C_{max} of digoxin following a single dose of digoxin (0.5 mg).

Metformin

Semaglutide did not change the overall exposure or C_{max} of metformin following dosing of 500 mg twice daily over 3.5 days.

Warfarin and other coumarin derivatives

Semaglutide did not change overall exposure or C_{max} of R- and S-warfarin following a single dose of warfarin (25 mg), and the pharmacodynamic effects of warfarin as measured by the international normalised ratio (INR) were not affected in a clinically relevant manner. However, cases of decreased INR have been reported during concomitant use of acenocoumarol and semaglutide. Upon initiation of semaglutide treatment in patients on warfarin or other coumarin derivatives, frequent monitoring of INR is recommended.

Paediatric population

Interaction studies have only been performed in adults.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Women of childbearing potential are recommended to use contraception when treated with semaglutide (see section 4.5).

Pregnancy

Studies in animals have shown reproductive toxicity (see section 5.3). There are limited data from the use of semaglutide in pregnant women. Therefore, semaglutide should not be used during pregnancy. If a patient wishes to become pregnant, or pregnancy occurs, semaglutide should be discontinued. Semaglutide should be discontinued at least 2 months before a planned pregnancy due to the long half-life (see section 5.2).

Breast-feeding

In lactating rats, semaglutide was excreted in milk. A risk to a breast-fed child cannot be excluded. Semaglutide should not be used during breast-feeding.

Fertility

The effect of semaglutide on fertility in humans is unknown. Semaglutide did not affect male fertility in rats. In female rats, an increase in oestrous length and a small reduction in number of ovulations were observed at doses associated with maternal body weight loss.

4.7 Effects on ability to drive and use machines

Semaglutide has no or negligible influence on the ability to drive or use machines. However, dizziness can be experienced mainly during the dose escalation period. Driving or use of machines should be done cautiously if dizziness occurs.

Patients with type 2 diabetes

If semaglutide is used in combination with a sulfonylurea or insulin, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines (see section 4.4).

4.8 Undesirable effects

Summary of safety profile

In four phase 3a trials, 2,650 adult patients were exposed to Wegovy®. The duration of the trials were 68 weeks. The most frequently reported adverse reactions were gastrointestinal

disorders including nausea, diarrhoea, constipation and vomiting.

Tabulated list of adverse reactions

Table 3 lists adverse reactions identified in clinical trials in adults and post-marketing reports. The frequencies are based on a pool of the phase 3a trials.

Adverse reactions associated with Wegovy® are listed by system organ class and frequency. Frequency categories are defined as: Very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$) and not known (cannot be estimated from the available data).

Table 3 Frequency of adverse reactions of semaglutide

MedDRA system organ class	Very common	Common	Uncommon	Rare	Not known
Immune system disorders				Anaphylactic reaction	
Metabolism and nutrition disorders		Hypoglycaemia in patients with type 2 diabetes ^a			
Nervous system disorders	Headache ^b	Dizziness ^b Dysgeusia ^{b,c} Dysaesthesia ^a			
Eye disorders		Diabetic retinopathy in patients with type 2 diabetes ^a			
Cardiac disorders			Hypotension Orthostatic hypotension Increased heart rate ^{a,c}		
Gastrointestinal disorders	Vomiting ^{a,b} Diarrhoea ^{a,b} Constipation ^{a,b} Nausea ^{a,b} Abdominal pain ^{b,c}	Gastritis ^{b,c} Gastrooesophageal reflux disease ^b Dyspepsia ^b Eructation ^b Flatulence ^b Abdominal distension ^b	Acute pancreatitis ^a Delayed gastric emptying		Intestinal obstruction
Hepatobiliary disorders		Cholelithiasis ^a			
Skin and subcutaneous tissue disorders		Hair loss ^a		Angioedema	

MedDRA system organ class	Very common	Common	Uncommon	Rare	Not known
General disorders and administration site conditions	Fatigue ^{b,c}	Injection site reactions ^c			
Investigations			Increased amylase ^c Increased lipase ^c		

a) See description of selected adverse reactions below

b) Mainly seen in the dose-escalation period

c) Grouped preferred terms

Description of selected adverse reactions

The below information on specific adverse reactions, unless otherwise specified, pertains to the phase 3a trials.

Gastrointestinal adverse reactions

Over the 68 weeks trial period, nausea occurred in 43.9% of patients when treated with semaglutide (16.1% for placebo), diarrhoea in 29.7% (15.9% for placebo) and vomiting in 24.5% (6.3% for placebo). Most events were mild to moderate in severity and of short duration. Constipation occurred in 24.2% of patients treated with semaglutide (11.1% for placebo) and was mild to moderate in severity and of longer duration. In patients treated with semaglutide, median duration of nausea was 8 days, vomiting 2 days, diarrhoea 3 days, and constipation 47 days.

Patients with moderate renal impairment (eGFR ≥ 30 to < 60 mL/min/1.73m²) may experience more gastrointestinal effects when treated with semaglutide.

The gastrointestinal events led to permanent treatment discontinuation in 4.3% of patients.

Acute pancreatitis

The frequency of adjudication-confirmed acute pancreatitis reported in phase 3a clinical trials was 0.2% for semaglutide and $< 0.1\%$ for placebo, respectively. In SELECT, the cardiovascular outcomes trial, the frequency of acute pancreatitis confirmed by adjudication was 0.2% for semaglutide and 0.3% for placebo.

Acute gallstone disease/Cholelithiasis

Cholelithiasis was reported in 1.6% and led to cholecystitis in 0.6% of patients treated with semaglutide. Cholelithiasis and cholecystitis was reported in 1.1% and 0.3%, respectively, of patients treated with placebo.

Hair loss

Hair loss was reported in 2.5% of patients treated with semaglutide and in 1.0% of patients treated with placebo. The events were mainly of mild severity and most patients recovered

while on continued treatment. Hair loss was reported more frequently in patients with a greater weight loss ($\geq 20\%$).

Increased heart rate

In the phase 3a trials, a mean increase of 3 beats per minute (bpm) from a baseline mean of 72 bpm was observed in patients treated with semaglutide. The proportions of subjects with an increase in pulse from baseline ≥ 10 bpm at any timepoint during the on-treatment period were 67.0% in the semaglutide group vs. 50.1% in the placebo group.

Immunogenicity

Consistent with the potentially immunogenic properties of medicinal products containing proteins or peptides, patients may develop antibodies following treatment with semaglutide. The proportion of patients testing positive for anti-semaglutide antibodies at any time post-baseline was low (2.9%) and no patients had anti-semaglutide neutralising antibodies or anti-semaglutide antibodies with endogenous GLP-1 neutralising effect at end-of-trial. During treatment, high semaglutide concentrations might have lowered the sensitivity of the assays, hence the risk of false negatives cannot be excluded. However, in subjects testing positive for antibodies during and after treatment, the presence of antibodies was transient and with no apparent impact on efficacy and safety.

Hypoglycaemia in patients with type 2 diabetes

In STEP 2, clinically significant hypoglycaemia was observed in 6.2% (0.1 events/patient year) of subjects treated with semaglutide compared with 2.5% (0.03 events/patient year) of subjects treated with placebo. Hypoglycaemia with semaglutide was seen both with and without concomitant use of sulfonylurea. One episode (0.2% of subjects, 0.002 events/patient year) was reported as severe in a subject not concomitantly treated with a sulfonylurea. The risk of hypoglycaemia was increased when semaglutide was used with a sulfonylurea.

In STEP-HFpEF-DM, clinically significant hypoglycaemia was observed in 4.2% of subjects in both the semaglutide and placebo groups when used in combination with sulfonylurea and/or insulin (0.065 events/patient year with semaglutide and 0.098 events/patient year with placebo).

Diabetic retinopathy in patients with type 2 diabetes

A 2-year clinical trial investigated semaglutide 0.5 mg and 1 mg vs. placebo in 3,297 patients with type 2 diabetes, with high cardiovascular risk, long duration of diabetes and poorly controlled blood glucose. In this trial, adjudicated events of diabetic retinopathy complications occurred in more patients treated with semaglutide (3.0%) compared to placebo (1.8%). This was observed in insulin-treated patients with known diabetic retinopathy. The treatment difference appeared early and persisted throughout the trial. In STEP 2, retinal disorders were reported by 6.9% of patients treated with Wegovy®, 6.2% of patients treated with semaglutide 1 mg, and 4.2% of patients treated with placebo. The majority of events were reported as diabetic retinopathy (4.0%, 2.7%, and 2.7%, respectively) and non-proliferative retinopathy (0.7%, 0%, and 0%, respectively).

Dysaesthesia

Events related to a clinical picture of altered skin sensation such as paraesthesia, pain of skin, sensitive skin, dysaesthesia and burning skin sensation were reported in 2.1% of patients treated with semaglutide 2.4 mg and 1.2% of patients treated with placebo. The events were mild to moderate in severity and most patients recovered while on continued treatment.

Paediatric population

In a clinical trial conducted in adolescents of 12 years to below 18 years with obesity or overweight with at least one weight-related comorbidity, 133 patients were exposed to Wegovy®. The trial duration was 68 weeks.

Overall, the frequency, type and severity of adverse reactions in the adolescents were comparable to that observed in the adult population. Cholelithiasis was reported in 3.8% of patients treated with Wegovy® and 0% of patients treated with placebo.

No effects on growth or pubertal development were found after 68 weeks of treatment.

Other special populations

In the SELECT and SUSTAIN 6 trials, in adults with established cardiovascular disease, the adverse reaction profile was similar to that seen in the weight management phase 3a trials.

In the HFpEF trials, in adults with obesity related heart failure with preserved ejection fraction (HFpEF), the adverse reaction profile was similar to that seen in the weight management phase 3a trials.

Reporting of suspected adverse reactions

Healthcare professionals are asked to report any suspected adverse reactions to Novo Nordisk Indonesia at IDJKAgree@novonordisk.com or to BPOM (Badan Pengawas Obat dan Makanan) at e-meso.pom.go.id.

4.9 Overdose

Overdose with semaglutide may be associated with gastrointestinal disorders which could lead to dehydration. In the event of overdose the patient should be observed for clinical signs and appropriate supportive treatment initiated.

5. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs used in diabetes, glucagon-like peptide-1 (GLP-1) analogues, ATC code: A10BJ06

Mechanism of action

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.

GLP-1 is a physiological regulator of appetite and calorie intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation.

Animal studies show that semaglutide works in the brain through the GLP-1 receptor. Semaglutide has direct effects on areas in the brain involved in homeostatic regulation of food intake in the hypothalamus and the brainstem. Semaglutide may affect the hedonic reward system through direct and indirect effects in brain areas including the septum, thalamus and amygdala.

Clinical studies show that semaglutide reduces energy intake, increases feelings of satiety, fullness and control of eating, reduces feelings of hunger, and frequency and intensity of cravings. In addition, semaglutide reduces the preference for high fat foods.

Semaglutide orchestrates the homeostatic and hedonic contributions with executive function to regulate caloric intake, appetite, reward and food choice.

In addition, in clinical studies semaglutide have shown to reduce blood glucose in a glucose dependent manner by stimulating insulin secretion and lowering glucagon secretion when blood glucose is high. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase. During hypoglycaemia, semaglutide diminishes insulin secretion and does not impair glucagon secretion.

GLP-1 receptors are also expressed in the heart, vasculature, immune system and kidneys. Semaglutide has a beneficial effect on plasma lipids, lowered systolic blood pressure and reduced inflammation in clinical studies. Furthermore, animal studies have shown that semaglutide attenuated the development of atherosclerosis and had an anti-inflammatory action in the cardiovascular system.

The mechanism of action of semaglutide for cardiovascular risk reduction is likely multifactorial, in part driven by weight loss effects and effects on known cardiovascular risk factors (reduction in blood pressure, improvements in lipid profile and glucose metabolism, and anti-inflammatory effects as demonstrated by reductions in high-sensitivity C-reactive protein (hsCRP)). The exact mechanism of cardiovascular risk reduction has not been established.

Pharmacodynamic effects

Appetite, energy intake and food choice

Semaglutide reduces appetite by increasing feelings of fullness and satiety, while lowering hunger and prospective food consumption. In a phase 1 trial, energy intake during an ad libitum meal was 35% lower with semaglutide compared to placebo after 20 weeks of dosing. This was supported by improved control of eating, less food cravings and a relative lower preference for high fat food. Food cravings were further assessed in STEP 5 by a Control of Eating Questionnaire (CoEQ). At week 104, the estimated treatment difference both for control of cravings and craving of savoury food significantly favoured semaglutide, whereas no clear effect was seen for craving of sweet food.

Fasting and postprandial lipids

Semaglutide 1 mg compared to placebo lowered fasting triglyceride and very low density lipoproteins (VLDL) concentrations by 12% and 21%, respectively. The postprandial

triglyceride and VLDL response to a high fat meal was reduced with >40%.

Clinical efficacy and safety

The efficacy and safety of semaglutide for weight management in combination with a reduced calorie intake and increased physical activity were evaluated in four 68 weeks double-blinded randomised placebo-controlled phase 3a trials (STEP 1-4). A total of 4,684 adult patients (2,652 randomised to treatment with semaglutide) were included in these trials. Furthermore, the two-year efficacy and safety of semaglutide compared to placebo were evaluated in a double-blinded randomised placebo-controlled phase 3b trial (STEP 5) including 304 patients (152 in treatment with semaglutide).

Treatment with semaglutide demonstrated superior, clinically meaningful, and sustained weight loss compared with placebo in patients with obesity (BMI ≥ 30 kg/m²), or overweight (BMI ≥ 27 kg/m² to < 30 kg/m²) and at least one weight-related comorbidity. Furthermore, across the trials, a higher proportion of patients achieved $\geq 5\%$, $\geq 10\%$, $\geq 15\%$ and $\geq 20\%$ weight loss with semaglutide compared with placebo. The reduction in body weight occurred irrespective of the presence of gastrointestinal symptoms such as nausea, vomiting or diarrhoea.

Treatment with semaglutide also showed statistically significant improvements in waist circumference, systolic blood pressure and physical functioning compared to placebo.

Efficacy was demonstrated regardless of age, sex, race, ethnicity, baseline body weight, BMI, presence of type 2 diabetes and level of renal function. Variations in efficacy existed within all subgroups. Relatively greater weight loss was observed in women and in patients without type 2 diabetes as well as in patients with a lower versus higher baseline body weight.

STEP 1: Weight management

In a 68-week double-blind trial, 1,961 patients with obesity (BMI ≥ 30 kg/m²), or with overweight (BMI ≥ 27 kg/m² to < 30 kg/m²) and at least one weight-related comorbidity were randomised to semaglutide or placebo. All patients were on a reduced-calorie diet and increased physical activity throughout the trial.

Weight loss occurred early and continued throughout the trial. At end of treatment (week 68), the weight loss was superior and clinically meaningful compared with placebo (see Table 4 and Figure 1). Furthermore, a higher proportion of patients achieved $\geq 5\%$, $\geq 10\%$, $\geq 15\%$ and $\geq 20\%$ weight loss with semaglutide compared with placebo (see Table 4). Among patients with prediabetes at baseline, a higher proportion of patients had a normo-glycaemic status at end of treatment with semaglutide compared to placebo (84.1% vs. 47.8%).

Table 4 STEP 1: Results at week 68

	Semaglutide 2.4 mg	Placebo
Full analysis set (N)	1,306	655
Body weight		
Baseline (kg)	105.4	105.2
Change (%) from baseline ^{1,2}	-14.9	-2.4


Difference (%) from placebo ¹ [95% CI]	-12.4 [-13.4; -11.5]*	-
Change (kg) from baseline	-15.3	-2.6
Difference (kg) from placebo ¹ [95% CI]	-12.7 [-13.7; -11.7]	-
Patients (%) achieving weight loss ≥5% ³	83.5*	31.1
Patients (%) achieving weight loss ≥10% ³	66.1*	12.0
Patients (%) achieving weight loss ≥15% ³	47.9*	4.8
Waist circumference (cm)		
Baseline	114.6	114.8
Change from baseline ¹	-13.5	-4.1
Difference from placebo ¹ [95% CI]	-9.4 [-10.3; -8.5]*	-
Systolic blood pressure (mmHg)		
Baseline	126	127
Change from baseline ¹	-6.2	-1.1
Difference from placebo ¹ [95% CI]	-5.1 [-6.3; -3.9]*	-

*p<0.0001 (unadjusted 2-sided) for superiority.

¹ Estimated using an ANCOVA model using multiple imputation based on all data irrespective of discontinuation of randomised treatment or initiation of other anti-obesity medication or bariatric surgery.

² During the trial, randomised treatment was permanently discontinued by 17.1% and 22.4% of patients randomised to semaglutide 2.4 mg and placebo, respectively. Assuming that all randomised patients stayed on treatment and did not receive additional anti-obesity therapies, the estimated changes from randomisation to week 68 for body weight based on a Mixed Model for Repeated Measures including all observations until first discontinuation were -16.9% and -2.4% for semaglutide 2.4 mg and placebo respectively.

³ Estimated from binary regression model based on same imputation procedure as in primary analysis.



Observed values for patients completing each scheduled visit, and estimates with multiple imputations (MI) from retrieved dropouts

Figure 1 STEP 1: Mean change in body weight (%) from baseline to week 68

Following the 68-week trial, a 52-week off-treatment extension was conducted including 327

patients who had completed the main trial period on the maintenance dose of semaglutide or placebo. In the off-treatment period from week 68 to week 120, mean body weight increased in both treatment groups. However, for patients that had been treated with semaglutide for the main trial period the weight remained 5.6% below baseline compared to 0.1% for the placebo group.

STEP 2: Weight management in patients with type 2 diabetes

In a 68-week, double-blind trial, 1,210 patients with overweight or obesity (BMI ≥ 27 kg/m²) and type 2 diabetes were randomised to either semaglutide 2.4 mg, semaglutide 1 mg once-weekly or placebo. Patients included in the trial had insufficiently controlled diabetes (HbA_{1c} 7–10%) and were treated with either: diet and exercise alone or 1–3 oral antidiabetic drugs. All patients were on a reduced-calorie diet and increased physical activity throughout the trial.

Treatment with semaglutide for 68 weeks resulted in superior and clinically meaningful reduction in body weight and in HbA_{1c} compared to placebo (see Table 5 and Figure 2).

Table 5 STEP 2: Results at week 68

	Semaglutide 2.4 mg	Placebo
Full analysis set (N)	404	403
Body weight		
Baseline (kg)	99.9	100.5
Change (%) from baseline ^{1,2}	-9.6	-3.4
Difference (%) from placebo ¹ [95% CI]	-6.2 [-7.3; -5.2]*	-
Change (kg) from baseline	-9.7	-3.5
Difference (kg) from placebo ¹ [95% CI]	-6.1 [-7.2; -5.0]	-
Patients (%) achieving weight loss $\geq 5\%$ ³	67.4*	30.2
Patients (%) achieving weight loss $\geq 10\%$ ³	44.5*	10.2
Patients (%) achieving weight loss $\geq 15\%$ ³	25.0*	4.3
Waist circumference (cm)		
Baseline	114.5	115.5
Change from baseline ¹	-9.4	-4.5
Difference from placebo ¹ [95% CI]	-4.9 [-6.0; -3.8]*	-
Systolic blood pressure (mmHg)		
Baseline	130	130
Change from baseline ¹	-3.9	-0.5
Difference from placebo ¹ [95% CI]	-3.4 [-5.6; -1.3]**	-
HbA_{1c} (mmol/mol (%))		
Baseline	65.3 (8.1)	65.3 (8.1)
Change from baseline ¹	-17.5 (-1.6)	-4.1 (-0.4)
Difference from placebo ¹ [95% CI]	-13.5 [-15.5; -11.4] (-1.2 [-1.4; -1.1])*	-


* $p < 0.0001$ (unadjusted 2-sided) for superiority; ** $p < 0.05$ (unadjusted 2-sided) for superiority

¹ Estimated using an ANCOVA model using multiple imputation based on all data irrespective of discontinuation of randomised treatment or initiation of other anti-obesity medication or bariatric surgery.

² During the trial, randomised treatment was permanently discontinued by 11.6% and 13.9%

of patients randomised to semaglutide 2.4 mg and placebo, respectively. Assuming that all randomised patients stayed on treatment and did not receive additional anti-obesity therapies, the estimated changes from randomisation to week 68 for body weight based on a Mixed Model for Repeated Measures including all observations until first discontinuation were -10.6% and -3.1% for semaglutide 2.4 mg and placebo respectively

³ Estimated from binary regression model based on same imputation procedure as in primary analysis.



Observed values for patients completing each scheduled visit, and estimates with multiple imputations (MI) from retrieved dropouts

Figure 2 STEP 2: Mean change in body weight (%) from baseline to week 68

STEP 3: Weight management with intensive behavioural therapy

In a 68-week double-blind trial, 611 patients with obesity (BMI ≥ 30 kg/m²), or with overweight (BMI ≥ 27 kg/m² to < 30 kg/m²) and at least one weight-related comorbidity were randomised to semaglutide or placebo. During the trial, all patients received intensive behavioural therapy (IBT) consisting of a very restrictive diet, increased physical activity and behavioural counselling.

Treatment with semaglutide and IBT for 68 weeks resulted in superior and clinically meaningful reduction in body weight compared to placebo (see Table 6).

Table 6 STEP 3: Results at week 68

	Semaglutide 2.4 mg	Placebo
Full analysis set (N)	407	204
Body weight		
Baseline (kg)	106.9	103.7
Change (%) from baseline ^{1,2}	-16.0	-5.7
Difference (%) from placebo ¹ [95% CI]	-10.3 [-12.0; -8.6]*	-
Change (kg) from baseline	-16.8	-6.2
Difference (kg) from placebo ¹ [95% CI]	-10.6 [-12.5; -8.8]	-
Patients (%) achieving weight loss $\geq 5\%$ ³	84.8*	47.8

Patients (%) achieving weight loss $\geq 10\%$ ³	73.0*	27.1
Patients (%) achieving weight loss $\geq 15\%$ ³	53.5*	13.2
Waist circumference (cm)		
Baseline	113.6	111.8
Change from baseline ¹	-14.6	-6.3
Difference from placebo ¹ [95% CI]	-8.3 [-10.1; -6.6]*	-
Systolic blood pressure (mmHg)		
Baseline	124	124
Change from baseline ¹	-5.6	-1.6
Difference from placebo ¹ [95% CI]	-3.9 [-6.4; -1.5]*	-

* $p < 0.005$ (unadjusted 2-sided) for superiority

¹ Estimated using an ANCOVA model using multiple imputation based on all data irrespective of discontinuation of randomised treatment or initiation of other anti-obesity medication or bariatric surgery.

² During the trial, randomised treatment was permanently discontinued by 16.7% and 18.6% of patients randomised to semaglutide 2.4 mg and placebo, respectively. Assuming that all randomised patients stayed on treatment and did not receive additional anti-obesity therapies, the estimated changes from randomisation to week 68 for body weight based on a Mixed Model for Repeated Measures including all observations until first discontinuation were -17.6% and -5.0% for semaglutide 2.4 mg and placebo respectively

³ Estimated from binary regression model based on same imputation procedure as in primary analysis.

STEP 4: Sustained weight management

In a 68-week double-blind trial, 902 patients with obesity (BMI ≥ 30 kg/m²), or with overweight (BMI ≥ 27 kg/m² to < 30 kg/m²) and at least one weight-related comorbidity were included in the trial. All patients were on a reduced-calorie diet and increased physical activity throughout the trial. From week 0 to week 20 (run-in), all patients received semaglutide. At week 20 (baseline), patients who had reached the maintenance dose of 2.4 mg were randomised to continue treatment or switch to placebo. At week 0 (start of run-in period) patients had a mean body weight of 107.2 kg and a mean BMI of 38.4 kg/m².

Patients who had reached the maintenance dose of 2.4 mg at week 20 (baseline) and continued treatment with semaglutide for 48 weeks (week 20–68) continued losing weight and had a superior and clinically meaningful reduction in body weight compared to those switched to placebo (see Table 7 and Figure 3). The body weight increased steadily from week 20 to week 68 in patients switching to placebo at week 20 (baseline). Nevertheless, the observed mean body weight was lower at week 68 than at start of the run-in period (week 0) (see Figure 3). Patients treated with semaglutide from week 0 (run-in) to week 68 (end of treatment) achieved a mean change in body weight of 17.4%, with weight loss $\geq 5\%$ achieved by 87.8%, $\geq 10\%$ achieved by 78.0%, $\geq 15\%$ achieved by 62.2% and $\geq 20\%$ achieved by 38.6% of these patients.

Table 7 STEP 4: Results from week 20 to week 68

	Semaglutide 2.4 mg	Placebo
Full analysis set (N)	535	268
Body weight		


Baseline ¹ (kg)	96.5	95.4
Change (%) from baseline ^{1,2,3}	-7.9	6.9
Difference (%) from placebo ² [95% CI]	-14.8 [-16.0; -13.5]*	-
Change (kg) from baseline	-7.1	6.1
Difference (kg) from placebo ² [95% CI]	-13.2 [-14.3; -12.0]	-
Waist circumference (cm)		
Baseline	105.5	104.7
Change from baseline ¹	-6.4	3.3
Difference from placebo ² [95% CI]	-9.7 [-10.9; -8.5]*	-
Systolic blood pressure (mmHg)		
Baseline ¹	121	121
Change from baseline ^{1,2}	0.5	4.4
Difference from placebo ² [95% CI]	-3.9 [-5.8; -2.0]*	-

* p<0.0001 (unadjusted 2-sided) for superiority,

¹ Baseline = week 20

² Estimated using an ANCOVA model using multiple imputation based on all data irrespective of discontinuation of randomised treatment or initiation of other anti-obesity medication or bariatric surgery.

³ During the trial, randomised treatment was permanently discontinued by 5.8% and 11.6% of patients randomized to semaglutide 2.4 mg and placebo, respectively. Assuming that all randomised patients stayed on treatment and did not receive additional anti-obesity therapies, the estimated changes from randomisation to week 68 for body weight based on a Mixed Model for Repeated Measures including all observations until first discontinuation were -8.8% and 6.5% for semaglutide 2.4 mg and placebo respectively.



Observed values for patients completing each scheduled visit, and estimates with multiple imputations (MI) from retrieved dropouts

Figure 3 STEP 4: Mean change in body weight (%) from week 0 to week 68

STEP 5: 2-year data

In a 104-week double-blind trial, 304 patients with obesity (BMI ≥ 30 kg/m²), or with overweight (BMI ≥ 27 to < 30 kg/m²) and at least one weight-related comorbidity, were

randomised to semaglutide or placebo. All patients were on a reduced-calorie diet and increased physical activity throughout the trial. At baseline, patients had a mean BMI of 38.5 kg/m², a mean body weight of 106.0 kg.

Treatment with semaglutide for 104 weeks resulted in a superior and clinically meaningful reduction in body weight compared to placebo. Mean body weight decreased from baseline through to week 68 with semaglutide after which a plateau was reached. With placebo, mean body weight decreased less, and a plateau was reached after approximately 20 weeks of treatment (see Table 8 and Figure 4). Patients treated with semaglutide achieved a mean change in body weight of -15.2%, with weight loss ≥5% achieved by 74.7%, ≥10% achieved by 59.2% and ≥15% achieved by 49.7% of these patients. Among patients with prediabetes at baseline, 80% and 37% achieved a normo-glycaemic status at end of treatment with semaglutide and placebo, respectively.

Table 8 STEP 5: Results at week 104


	Semaglutide 2.4 mg	Placebo
Full analysis set (N)	152	152
Body weight		
Baseline (kg)	105.6	106.5
Change (%) from baseline ^{1,2}	-15.2	-2.6
Difference (%) from placebo ¹ [95% CI]	-12.6 [-15.3; -9.8]*	-
Change (kg) from baseline	-16.1	-3.2
Difference (kg) from placebo ¹ [95% CI]	-12.9 [-16.1; -9.8]	-
Patients (%) achieving weight loss ≥5% ³	74.7*	37.3
Patients (%) achieving weight loss ≥10% ³	59.2*	16.8
Patients (%) achieving weight loss ≥15% ³	49.7*	9.2
Waist circumference (cm)		
Baseline	115.8	115.7
Change from baseline ¹	-14.4	-5.2
Difference from placebo ¹ [95% CI]	-9.2 [-12.2; -6.2]*	-
Systolic blood pressure (mmHg)		
Baseline	126	125
Change from baseline ¹	-5.7	-1.6
Difference from placebo ¹ [95% CI]	-4.2 [-7.3; -1.0]*	-

* p<0.0001 (unadjusted 2-sided) for superiority.

¹ Estimated using an ANCOVA model using multiple imputation based on all data irrespective of discontinuation of randomised treatment or initiation of other anti-obesity medication or bariatric surgery.

² During the trial, randomised treatment was permanently discontinued by 13.2% and 27.0% of patients randomised to semaglutide 2.4 mg and placebo, respectively. Assuming that all randomised patients stayed on treatment and did not receive additional anti-obesity therapies, the estimated changes from randomisation to week 104 for body weight based on a Mixed Model for Repeated Measures including all observations until first discontinuation were -16.7% and -0.6% for semaglutide and placebo respectively.

³ Estimated from binary regression model based on same imputation procedure as in primary analysis.



Observed values for patients completing each scheduled visit, and estimates with multiple imputations (MI) from retrieved dropouts

Figure 4 STEP 5: Mean change in body weight (%) from week 0 to week 104

STEP 8: Semaglutide vs liraglutide

In a 68-week, randomised, open-label, pairwise placebo-controlled trial, 338 patients with obesity (BMI ≥ 30 kg/m²), or with overweight (BMI ≥ 27 to < 30 kg/m²) and at least one weight-related comorbidity, were randomised to semaglutide once weekly, liraglutide 3 mg once daily or placebo. Semaglutide once weekly and liraglutide 3 mg were open-label, but each active treatment group was double-blinded against placebo administered at the same dosing frequency. All patients were on a reduced-calorie diet and increased physical activity throughout the trial. At baseline, patients had a mean BMI of 37.5 kg/m², a mean body weight of 104.5 kg.

Treatment with semaglutide once weekly for 68 weeks resulted in superior and clinically meaningful reduction in body weight compared to liraglutide. Mean body weight decreased from baseline through to week 68 with semaglutide. With liraglutide, mean body weight decreased less (see Table 9). 37.4% of the patients treated with semaglutide lost $\geq 20\%$, compared to 7.0% treated with liraglutide. Table 9 shows the results of the confirmatory endpoints $\geq 10\%$, $\geq 15\%$ and $\geq 20\%$ weight loss.

Table 9 STEP 8: Results of a 68-week trial comparing semaglutide with liraglutide

	Semaglutide 2.4 mg	Liraglutide 3 mg
Full analysis set (N)	126	127
Body weight		
Baseline (kg)	102.5	103.7
Change (%) from baseline ^{1, 2}	-15.8	-6.4
Difference (%) from liraglutide ¹ [95% CI]	-9.4 [-12.0; -6.8]*	-
Change (kg) from baseline	-15.3	-6.8
Difference (kg) from liraglutide ¹ [95% CI]	-8.5 [-11.2; -5.7]	-
Patients (%) achieving weight loss $\geq 10\%$ ³	69.4*	27.2
Patients (%) achieving weight loss $\geq 15\%$ ³	54.0*	13.4

Patients (%) achieving weight loss $\geq 20\%$ ³	37.4*	7.0
---	-------	-----

* $p < 0.005$ (unadjusted 2-sided) for superiority.

¹ Estimated using an ANCOVA model using multiple imputation based on all data irrespective of discontinuation of randomised treatment or initiation of other anti-obesity medication or bariatric surgery.

² During the trial, randomised treatment was permanently discontinued by 13.5% and 27.6% of patients randomised to semaglutide 2.4 mg and liraglutide 3 mg, respectively. Assuming that all randomised patients stayed on treatment and did not receive additional anti-obesity therapies, the estimated changes from randomisation to week 68 for body weight based on a Mixed Model for Repeated Measures including all observations until first discontinuation were -16.7% and -6.7% for semaglutide 2.4 mg and liraglutide 3 mg respectively.

³ Estimated from binary regression model based on same imputation procedure as in primary analysis.

STEP 9: Weight management in patients with knee osteoarthritis

In a 68-week double-blind trial, 407 patients with obesity and moderate knee osteoarthritis (OA) of one or both knees were randomised to either semaglutide or placebo, as an adjunct to counselling on a reduced-calorie diet and increased physical activity. The treatment effect on knee OA-related pain was assessed by the Western Ontario and McMaster Universities Osteoarthritis 3.1 Index (WOMAC). This index is designed to evaluate changes in symptoms and lower extremity functioning associated with treatment in patients suffering from OA of the hip and/or knee. At baseline, patients had a mean BMI of 40.3 kg/m² and a mean body weight of 108.6 kg. All patients had a clinical diagnosis of knee OA with a mean baseline WOMAC pain score of 70.9 (on a scale of 0-100).

Treatment with semaglutide for 68 weeks resulted in superior and clinically significant reduction in body weight compared to placebo (see Table 10).

Treatment with semaglutide demonstrated a clinically meaningful improvement in knee OA-related pain compared to the placebo (see Table 10). The improvements in knee OA-related pain with semaglutide were achieved without an increase in the use of pain medication.

Table 10 STEP 9: Results at week 68

	Semaglutide 2.4 mg	Placebo
Full analysis set (N)	271	136
Body weight		
Baseline (kg)	108.7	108.5
Change (%) from baseline ^{1,2}	-13.7	-3.2
Difference (%) from placebo ¹ [95% CI]	-10.5 [-12.3; -8.6]*	-
Patients (%) achieving weight loss $\geq 5\%$ ³	85.2*	33.6
WOMAC pain score⁴		
Baseline	72.8	67.2
Change from baseline ^{1,2}	-41.7	-27.5
Difference from placebo ¹ [95% CI]	-14.1 [-20.0; -8.3]*	-
Patients (%) achieving clinically meaningful improvement ^{3,5}	59.0	35.0

* $p < 0.0001$ (unadjusted 2-sided) for superiority.

¹ Estimated using an ANCOVA model using multiple imputation based on all data irrespective of discontinuation of randomised treatment or initiation of other anti-obesity therapies or other knee OA interventions and regardless of compliance with wash out period for pain medication (the latter only relevant for WOMAC related endpoint). During the trial, randomised treatment was permanently discontinued by 12.5% and 21.3% of patients randomised to semaglutide 2.4 mg and placebo, respectively.

² Based on a Mixed Model for Repeated Measures assuming that all randomised patients stayed on treatment and did not receive additional anti-obesity therapies or additional knee OA interventions and complied with washout period for pain medication (the latter only relevant for knee OA related pain), including all observations until first discontinuation the estimated changes from baseline to week 68 for body weight were -14.5% and -2.3% (semaglutide 2.4 mg and placebo, respectively) and for WOMAC pain score: -43.0 and -28.3 (semaglutide 2.4 mg and placebo, respectively).

³ Estimated from logistic regression model based on same imputation procedure as for the primary analysis.

⁴ WOMAC scores are presented on a scale from 0-100, with lower scores representing less disability.

⁵ The change in WOMAC pain score of ≤ -37.3 was used as a threshold for meaningful improvement. The threshold was derived from trial data using anchor-based methods.

Effect on body composition

In a sub-study in STEP 1 (N = 140), body composition was measured using dual energy X-ray absorptiometry (DEXA). The results of the DEXA assessment showed that treatment with semaglutide was accompanied by greater reduction in fat mass than in lean body mass leading to an improvement in body composition compared to placebo after 68 weeks. Furthermore, this reduction in total fat mass was accompanied by a reduction in visceral fat. These results suggest that most of the total weight loss was attributable to a reduction in fat tissue, including visceral fat.

Improvement in physical functioning

Semaglutide showed small improvements in physical functioning scores. Physical functioning was assessed using both the generic health-related quality of life questionnaire Short Form-36v2 Health Survey, Acute Version (SF-36) and the obesity-specific questionnaire Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT).

Cardiovascular evaluation

SELECT: Cardiovascular outcomes trial in patients with overweight or obesity

SELECT was a randomised, double-blind, placebo-controlled, event driven trial which included 17,604 patients with established cardiovascular disease and BMI ≥ 27 kg/m². Patients were randomised to either semaglutide 2.4 mg (n=8 803) or placebo (n=8 801) in addition to standard-of-care. The median time in trial was 41.8 months. Vital status was available for 99.4% of subjects in the trial.


The study population consisted of 27.7 % female and 72.3 % male patients, with a mean age of 61.6 years, including 38.2 % patients ≥ 65 years (n=6 728) and 7.8 % patients ≥ 75 years

(n=1 366). The mean BMI was 33.3 kg/m² and mean body weight was 96.7 kg. Patients with history of type 1 and type 2 diabetes were excluded.

The primary endpoint was the time from randomisation to first occurrence of major adverse cardiovascular events (MACE), defined as a composite endpoint consisting of cardiovascular death (including undetermined cause of death), non-fatal myocardial infarction, or non-fatal stroke. The primary endpoint, time to first MACE, occurred in 1 270 of the 17 604 patients included in the SELECT trial. Specifically, 569 first MACE (6.5%) were recorded among the 8 803 patients treated with semaglutide, compared to 701 first MACE (8.0%) among the 8 801 patients treated with placebo. A total of 63 (11.1%) of the first MACE with semaglutide and 80 (11.4%) with placebo were undetermined cause of death.

Superiority of semaglutide 2.4 mg versus placebo for MACE was confirmed with a hazard ratio of 0.80 [0.72; 0.90][95% CI], corresponding to a relative risk reduction in MACE of 20 % (see Figure 5). The effect on each component to the reduction of MACE is shown in Figure 6. The reduction of MACE with semaglutide 2.4 mg was not impacted by age, sex, race, ethnicity, BMI at baseline, or level of renal function impairment.

Analysis of the cardiovascular death (the first confirmatory secondary endpoint) resulted in a hazard ratio of 0.85 [0.71; 1.01][95% CI].




Data from the in-trial period. Cumulative incidence estimates are based on time from randomisation to first EAC-confirmed MACE with non-CV death modelled as competing risk using the Aalen-Johansen estimator. Subjects without events of interest were censored at the end of their in-trial observation period. Time from randomisation to first MACE was analysed using a Cox proportional hazards model with treatment as categorical fixed factor. The hazard ratio and confidence interval are adjusted for the group sequential design using the likelihood ratio ordering. The x-axis is truncated at 50 months where approximately 10% of the population was still in the trial.

HR: hazard ratio, CI: Confidence interval, Sema 2.4 mg: semaglutide 2.4 mg.

CV: cardiovascular, EAC: event adjudication committee, MACE: major adverse cardiovascular event.

Figure 5: Time from randomisation to first MACE Cumulative incidence function plot



Data from the in-trial period. Time from randomisation to each endpoint was analysed using a Cox proportional hazards model with treatment as categorical fixed factor. Subjects without events of interest were censored at the end of their in-trial period. For the primary endpoint the HR and CI were adjusted for the group sequential design using likelihood ratio ordering. Secondary endpoints are not under multiplicity control. CV death includes both cardiovascular death and undetermined cause of death.
 HR: hazard ratio, CI: Confidence interval, Sema 2.4 mg: semaglutide 2.4 mg.
 CV: cardiovascular, MI: myocardial infarction, Heart failure (HF) composite consisting of HF hospitalisation, urgent HF visit or CV death.

Figure 6: Forest plot of time from randomisation to first MACE, MACE components and secondary confirmatory endpoints

SUSTAIN 6: Cardiovascular outcomes trial in patients with type 2 diabetes

In the SUSTAIN 6 trial, 3,297 patients with insufficiently controlled type 2 diabetes and at high risk of cardiovascular events were randomised to semaglutide s.c. 0.5 mg or 1 mg once-weekly or placebo in addition to standard-of-care. The treatment duration was 104 weeks. The mean age was 65 years and the mean BMI was 33 kg/m².

The primary endpoint was the time from randomisation to first occurrence of a major adverse cardiovascular event (MACE): cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. The total number of the MACE was 254, including 108 (6.6%) with semaglutide and 146 (8.9%) with placebo.

The cardiovascular safety of treatment with semaglutide 0.5 or 1 mg was confirmed as the hazard ratio (HR) for semaglutide vs. placebo was 0.74, [0.58, 0.95] [95% CI], driven by a decrease in the rate of non-fatal stroke and non-fatal myocardial infarction with no difference in cardiovascular death (see Figure 7).




Figure 7: Kaplan-Meier plot of time to first occurrence of the composite outcome: Cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (SUSTAIN 6)

STEP-HFpEF and STEP-HFpEF-DM: Functional outcome trials in patients with heart failure with preserved ejection fraction without and with type 2 diabetes

In two 52-week double-blinded clinical trials, 529 patients with obesity-related heart failure with preserved ejection fraction (STEP-HFpEF), and 616 patients with obesity-related HFpEF and type 2 diabetes (STEP-HFpEF-DM) were randomised to be treated with either semaglutide 2.4 mg or placebo once weekly in addition to standard of care treatment.

At baseline, 66.2% and 70.6% of the patients were classified as New York Heart Association (NYHA) class II, 33.6% and 29.2% were NYHA class III and 0.2% and 0.2% were NYHA class IV, in STEP-HFpEF and STEP HFpEF-DM respectively. Mean age was 68 years in both trials, median left ventricular ejection fraction (LVEF) was 57.0% and 56.0%, and mean BMI was 38.5 kg/m² and 37.9 kg/m². The STEP-HFpEF trial included 56.1% females, whereas 44.3% were female in STEP-HFpEF-DM. A high proportion of patients were on cardiovascular medications including ~ 81% on diuretics, ~ 81% on beta blockers, ~ 34% on angiotensin converting enzyme (ACE) inhibitors and ~ 45% on angiotensin receptor blockers (ARBs).

In STEP-HFpEF-DM patients were also receiving standard of care glucose lowering medications of which 32.8% were treated with sodium/glucose cotransporter-2 inhibitor (SGLT-2i) and 20.8% were treated with insulin.

The treatment effect of semaglutide 2.4 mg on heart failure symptoms was assessed using the Clinical Summary Score of the Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS) which includes the domains of symptom (frequency and burden) and physical limitation. The score ranges from 0 to 100, with higher scores representing better health status. The treatment effect of semaglutide 2.4 mg on 6-Minute Walk Distance (6MWD) was assessed by the 6-Minute Walk Test (6MWT). Baseline values of KCCQ-CSS and 6MWD reflect a highly symptomatic population.

In both trials treatment with semaglutide 2.4 mg resulted in a superior effect on both KCCQ-CSS and 6MWD (Table 11). Benefits were seen both in heart failure symptoms and physical function.

Table 11 Results of 6MWD, KCCQ-CSS and body weight from the two 52-week randomised trials (STEP-HFpEF and STEP-HFpEF-DM)

	STEP-HFpEF		STEP-HFpEF-DM	
	Semaglutide 2.4 mg	Placebo	Semaglutide 2.4 mg	Placebo
Full analysis set (N)	263	266	310	306
KCCQ-CSS (score)				
Baseline (mean) ¹	57.9	55.5	58.8	56.4
Change from baseline ²	16.6	8.7	13.7	6.4
Difference from placebo ² [95% CI]	7.8 [4.8; 10.9]		7.3 [4.1; 10.4]	
Patients (%) experiencing meaningful change ³	43.2	32.5	42.7	30.5
6MWD (metres)				
Baseline (mean) ¹	319.6	314.6	279.7	276.7
Change from baseline ²	21.5	1.2	12.7	-1.6
Difference from placebo ² [95% CI]	20.3 [8.6; 32.1]		14.3 [3.7; 24.9]	
Patients (%) with meaningful change ⁴	47.9	34.7	43.8	30.6
Body weight				
Baseline (kg) ¹	108.3	108.4	106.4	105.2
Change (%) from baseline ²	-13.3	-2.6	-9.8	-3.4
Difference (%) from placebo ² [95% CI]	-10.7 [-11.9; -9.4]		-6.4 [-7.6; -5.2]	

¹ Observed mean.

² Estimated using an ANCOVA model using multiple and for KCCQ and 6MWD, also a composite imputation based on all data irrespective of discontinuation of randomised treatment or initiation of other anti-obesity medication or bariatric surgery.

³ Meaningful within patient change threshold of 17.2 points for STEP-HFpEF trial and 16.3 points for STEP-HFpEF-DM trial (derived using an anchor-based method based on a 1-category improvement in Patient Global Impression of Status (PGI-S)). Percentages are based on subjects with an observation at the visit.

⁴ Meaningful within patient change threshold of 22.1 metres for STEP-HFpEF trial and 25.6 metres for STEP-HFpEF-DM trial (derived using an anchor-based method using “moderately better” in Patient Global Impression of Change (PGI-C)). Percentages are based on subjects with an observation at the visit.

The treatment benefit of semaglutide over placebo was consistent across all subpopulations defined by age, sex, BMI, race, ethnicity, region, systolic blood pressure (SBP), LVEF and concomitant heart failure therapy.

STEP TEENS: Weight management in adolescent patients

In a 68-week double-blind trial 201 pubertal adolescents, ages 12 to less than 18 years, with obesity or overweight and at least one weight-related comorbidity were randomised 2:1 to semaglutide or placebo. Prepubertal subjects (Tanner stage 1) were excluded from this study. All patients were on a reduced-calorie diet and increased physical activity throughout the trial.

At end of treatment (week 68), the improvement in BMI with semaglutide was superior and clinically meaningful compared with placebo (see Table 12 and Figure 8). Furthermore, a higher proportion of patients achieved $\geq 5\%$, 10% and $\geq 15\%$ weight loss with semaglutide compared with placebo (see Table 12).

Table 12 STEP TEENS: Results at week 68

	Semaglutide 2.4 mg	Placebo
Full analysis set (N)	134	67
BMI		
Baseline (BMI)	37.7	35.7
Change (%) from baseline ^{1,2}	-16.1	0.6
Difference (%) from placebo ¹ [95% CI]	-16.7 [-20.3; -13.2]*	-
Baseline (BMI SDS)	3.4	3.1
Change from baseline in BMI SDS ¹	-1.1	-0.1
Difference from placebo ¹ [95% CI]	-1.0 [-1.3; -0.8]	-
Body Weight		
Baseline (kg)	109.9	102.6
Change (%) from baseline ¹	-14.7	2.8
Difference (%) from placebo ¹ [95% CI]	-17.4 [-21.1; -13.8]	-
Change (kg) from baseline ¹	-15.3	2.4
Difference (kg) from placebo ¹ [95% CI]	-17.7 [-21.8; -13.7]	-
Patients (%) achieving weight loss $\geq 5\%$ ³	72.5*	17.7
Patients (%) achieving weight loss $\geq 10\%$ ³	61.8	8.1
Patients (%) achieving weight loss $\geq 15\%$ ³	53.4	4.8
Waist circumference (cm)		
Baseline	111.9	107.3
Change from baseline ¹	-12.7	-0.6
Difference from placebo ¹ [95% CI]	-12.1 [-15.6; -8.7]	-
Systolic blood pressure (mmHg)		
Baseline	120	120
Change from baseline ¹	-2.7	-0.8
Difference from placebo ¹ [95% CI]	-1.9 [-5.0; 1.1]	-


* $p < 0.0001$ (unadjusted 2-sided) for superiority.

¹ Estimated using an ANCOVA model using multiple imputation based on all data irrespective of discontinuation of randomised treatment or initiation of other anti-obesity medication or bariatric surgery.

² During the trial, randomised treatment was permanently discontinued by 10.4% and 10.4% of patients randomised to semaglutide 2.4 mg and placebo, respectively. Assuming that all

randomised patients stayed on treatment and did not receive additional anti-obesity therapies, the estimated changes from randomisation to week 68 for BMI based on a Mixed Model for Repeated Measures including all observations until first discontinuation were -17.9% and 0.6% for semaglutide 2.4 mg and placebo respectively

³ Estimated from logistic regression model based on same imputation procedure as in primary analysis.



Observed values for patients completing each scheduled visit, and estimates with multiple imputations (MI) from retrieved dropouts

Figure 8 STEP TEENS: Mean change in BMI (%) from baseline to week 68

5.2 Pharmacokinetic properties

Semaglutide is not a pro-drug. There is no active metabolite in semaglutide. Chirality is not applicable for semaglutide. Semaglutide is freely soluble in the water. Pharmacokinetic data were obtained from subjects with obesity or overweight in phase 3 trials and also been investigated in healthy subjects and subjects with type 2 diabetes.

Compared to native GLP-1, semaglutide has a prolonged half-life of around 1 week making it suitable for once weekly subcutaneous administration. The principal mechanism of protraction is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilised against degradation by the DPP-4 enzyme.

Absorption

The average semaglutide steady state concentration following s.c. administration of the semaglutide maintenance dose was approximately 75 nmol/L in patients with overweight (BMI ≥ 27 kg/m² to < 30 kg/m²) or obesity (BMI ≥ 30 kg/m²) based on data from phase 3a trials, where 90% of patients had average concentrations between 51 nmol/L and 110 nmol/L. The steady state exposure of semaglutide increased proportionally with doses from 0.25 mg up to 2.4 mg once weekly. Steady state exposure was stable with time as assessed up to week 68. Similar exposure was achieved with s.c. administration of semaglutide in the abdomen, thigh, or upper arm. The absolute bioavailability of semaglutide

was 89%.

Distribution

The mean volume of distribution of semaglutide following s.c. administration in patients with overweight or obesity was approximately 12.4 L. Semaglutide is extensively bound to plasma albumin (>99%).

Metabolism/biotransformation

Prior to excretion, semaglutide is extensively metabolised through proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain. The enzyme neutral endopeptidase (NEP) was identified as one of the active metabolic enzymes.

Elimination

The primary excretion routes of semaglutide-related material are via the urine and faeces. Approximately 3% of the absorbed dose was excreted in the urine as intact semaglutide. The clearance of semaglutide in patients with overweight (BMI ≥ 27 kg/m² to < 30 kg/m²) or obesity (BMI ≥ 30 kg/m²) was approximately 0.05 L/h. With an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for approximately 7 weeks after the last dose of 2.4 mg.

Special populations

Elderly

Age had no effect on the pharmacokinetics of semaglutide based on data from phase 3 trials including patients 18–86 years of age.

Gender, race and ethnicity

Gender, race (White, Black or African American, Asian) and ethnicity (Hispanic or Latino, non-Hispanic or -Latino) had no effect on the pharmacokinetics of semaglutide based on data from phase 3a trials.

Body weight

Body weight had an effect on the exposure of semaglutide. Higher body weight was associated with lower exposure; a 20% difference in body weight between individuals will result in an approximate 18% difference in exposure. The 2.4 mg weekly dose of semaglutide provided adequate systemic exposures over the body weight range of 54.4–245.6 kg evaluated for exposure response in the clinical trials.

Renal impairment

Renal impairment did not impact the pharmacokinetics of semaglutide in a clinically relevant manner. This was shown with a single dose of 0.5 mg semaglutide for patients with different degrees of renal impairment (mild, moderate, severe or patients in dialysis) compared with patients with normal renal function. This was also shown for patients with overweight (BMI ≥ 27 kg/m² to < 30 kg/m²) or obesity (BMI ≥ 30 kg/m²) and mild to moderate renal impairment based on data from phase 3a trials.

Hepatic impairment

Hepatic impairment did not have any impact on the exposure of semaglutide. The

pharmacokinetics of semaglutide were evaluated in patients with different degrees of hepatic impairment (mild, moderate, severe) and compared with patients with normal hepatic function in a study with a single dose of 0.5 mg semaglutide.

Prediabetes and diabetes

Prediabetes and diabetes did not have any clinically relevant effect on the exposure of semaglutide based on data from phase 3 trials.

Immunogenicity

Development of anti-semaglutide antibodies when treated with semaglutide occurred infrequently (see section 4.8) and the response did not appear to influence semaglutide pharmacokinetics.

Paediatrics

Pharmacokinetic properties for semaglutide were assessed in a clinical trial for adolescent patients with obesity or overweight and at least one weight-related comorbidity ages 12 to <18 years (124 patients, body weight 61.6-211.9 kg). The semaglutide exposure in adolescents was similar to that in adults with obesity or overweight.

Safety and efficacy of semaglutide in children below 12 years of age have not been studied.

5.3 Preclinical safety data

Preclinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeat-dose toxicity or genotoxicity.

Non-lethal thyroid C-cell tumours observed in rodents are a class effect for GLP-1 receptor agonists. In 2-year carcinogenicity studies in rats and mice, semaglutide caused thyroid C-cell tumours at clinically relevant exposures. No other treatment-related tumours were observed. The rodent C-cell tumours are caused by a non-genotoxic, specific GLP-1 receptor mediated mechanism to which rodents are particularly sensitive. The relevance for humans is considered to be low, but cannot be completely excluded.

In fertility studies in rats, semaglutide did not affect mating performance or male fertility. In female rats, an increase in oestrous cycle length and a small reduction in corpora lutea (ovulations) were observed at doses associated with maternal body weight loss.

In embryo-foetal development studies in rats, semaglutide caused embryotoxicity below clinically relevant exposures. Semaglutide caused marked reductions in maternal body weight and reductions in embryonic survival and growth. In foetuses, major skeletal and visceral malformations were observed, including effects on long bones, ribs, vertebrae, tail, blood vessels and brain ventricles. Mechanistic evaluations indicated that the embryotoxicity involved a GLP-1 receptor mediated impairment of the nutrient supply to the embryo across the rat yolk sac. Due to species differences in yolk sac anatomy and function, and due to lack of GLP-1 receptor expression in the yolk sac of non-human primates, this mechanism is considered unlikely to be of relevance to humans. However, a direct effect of semaglutide on the foetus cannot be excluded.

In developmental toxicity studies in rabbits and cynomolgus monkeys, increased pregnancy

loss and slightly increased incidence of foetal abnormalities were observed at clinically relevant exposures. The findings coincided with marked maternal body weight loss of up to 16%. Whether these effects are related to the decreased maternal food consumption as a direct GLP-1 effect is unknown.

Postnatal growth and development were evaluated in cynomolgus monkeys. Infants were slightly smaller at delivery but recovered during the lactation period.

In juvenile rats, semaglutide caused delayed sexual maturation in both males and females. These delays had no impact upon fertility and reproductive capacity of either sex, or on the ability of the females to maintain pregnancy.

6. Pharmaceutical particulars

6.1 List of excipients

Disodium phosphate, dihydrate
Propylene glycol
Phenol
Hydrochloric acid (for pH adjustment)
Sodium hydroxide (for pH adjustment)
Water for injections

6.2 Incompatibilities

In the absence of compatibility studies this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

36 months

Before use: Expiry date is stated on the pen label and carton after 'Expiry'.

After first use: 6 weeks. Store below 30°C or in a refrigerator (2°C to 8°C).

6.4 Special precautions for storage

Store in a refrigerator (2°C to 8°C). Keep away from the cooling element.

Do not freeze.

Keep the pen cap on when the pen is not in use in order to protect it from light.

6.5 Nature and contents of container

Pre-filled pen, FlexTouch® (0.25, 0.5 mg/dose) 1.5 mL pre-filled pen

1.5 mL glass cartridge (type I glass) closed at the one end with a rubber plunger (chlorobutyl) and at the other end with an aluminium cap with a laminated rubber sheet (bromobutyl/polyisoprene) inserted. The cartridge is assembled into a disposable pre-filled pen made of polypropylene, polyoxymethylene, polycarbonate and acrylonitrile butadiene styrene.

Pre-filled pen, FlexTouch® (1, 1.7 and 2.4 mg/dose) 3 mL pre-filled pen

3 mL glass cartridge (type I glass) closed at the one end with a rubber plunger (chlorobutyl) and at the other end with an aluminium cap with a laminated rubber sheet

(bromobutyl/polyisoprene) inserted. The cartridge is assembled into a disposable pre-filled pen made of polypropylene, polyoxymethylene, polycarbonate and acrylonitrile butadiene styrene.

Pack size

1 pre-filled pen and 4 disposable NovoFine® Plus needles.

HARUS DENGAN RESEP DOKTER

Reg. No.: DK12464605443A1 (0.25 mg/dose; 0.68 mg/mL)

DK12464605443B1 (0.5 mg/dose; 1.34 mg/mL)

DK12464605443B1 (1 mg/dose; 1.34 mg/mL)

DK12464605443C1 (1.7 mg/dose; 2.27 mg/mL)

DK12464605443D1 (2.4 mg/dose; 3.2 mg/mL)

6.6 Special precautions for disposal and other handling

Wegovy® should not be used if it does not appear clear and colourless.

The pen should not be used if it has been frozen.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

This pen is for multi-use. It contains 4 doses.

The patient should be advised to discard the injection needle in accordance with local requirements after each injection and store the Wegovy® pen without an injection needle attached. This may prevent blocked needles, contamination, infection, leakage of solution and inaccurate dosing.

The pen is for use by one person only.

Wegovy® can be administered with needles up to a length of 8 mm. The pen is designed to be used with NovoFine® and NovoTwist® disposable needles.

7. Manufactured by:

Novo Nordisk A/S
Brennum Park
DK-3400 Hillerød
Denmark

Released by:

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark

Registered by:

PT Beta Pharmacon

Karawang – Indonesia

Distributed by:

PT Anugrah Argon Medica
Indonesia

Based on approval date:

Wegovy®, *FlexTouch®*, *NovoFine®* and *NovoTwist®* are trademarks owned by Novo Nordisk A/S, Denmark

© 2025
Novo Nordisk A/S

Front page information:

Wegovy®

0.25 mg/dose, 0.5 mg/dose

1 mg/dose, 1.7 mg/dose

2.4 mg/dose

FlexTouch®

semaglutide

Instructions on how to use Wegovy®

Before you begin using your once-weekly Wegovy® FlexTouch® pen, **always read these instructions carefully**, and talk to your doctor, nurse or pharmacist about how to inject Wegovy® correctly.

Wegovy® pen is a dial-a-dose pen that **contains four of your prescribed doses of Wegovy®**, corresponding to four times of once-weekly use.

Please use the table inside the lid of the carton to keep track of how many injections you have used and how many doses remain in your pen.

Wegovy® comes in five different pens, each containing one of the following prescribed doses of semaglutide:

0.25 mg

0.5 mg

1 mg

1.7 mg

2.4 mg

Always start by checking your pen label to make sure that it contains your prescribed dose of Wegovy®.

Your pen is designed to be used with NovoFine® Plus, NovoFine® or NovoTwist® disposable needles up to a length of 8 mm.


The pack contains:

- Wegovy® pen
- 4 NovoFine® Plus needles
- Package leaflet


Wegovy® FlexTouch® pen (example)

Please note: Your pen may differ in size and your pen label may differ in colour from the example shown in the pictures.

These instructions apply to all Wegovy® FlexTouch® pens



NovoFine® Plus needle (example)




1 Prepare your pen with a new needle

Check the name and dose of your pen to make sure it contains your prescribed dose of Wegovy®.

Pull off the pen cap.


(See figure A).



Check that the solution in your pen is clear and colourless.

Look through the pen window. If Wegovy® looks cloudy or coloured, do not use the pen.

(See figure B).




Always use a new needle for each injection.

Take a needle when you are ready to take your injection. Check the paper tab and the outer needle cap for damages that could affect sterility. If any damage is seen, use a new needle.


Tear off the paper tab.

(See figure C).



Push the needle straight onto the pen. Turn until it is on tight.

(See figure D).



The needle is covered by two caps. You must remove both caps.


If you forget to remove both caps you will not inject any Wegovy®.

Pull off the outer needle cap and keep it for later. You will need it to safely remove the needle from the pen after the injection.

Pull off the inner needle cap and dispose of it. A drop of Wegovy® may appear at the needle tip. You must still check the Wegovy® flow if you use a new pen for the first time. See **'Check the flow with each new pen'**.

Never use a bent or damaged needle. For more information about needle handling, see **'About your needles'** below these instructions.

(See figure E).



Check the flow with each new pen

If your Wegovy® pen is already in use, go to **'2 Set your dose'**.

Only check the Wegovy® flow before your **first injection with each new pen**.

Turn the dose selector until you see the flow check symbol ().

(See figure F).



Make sure the flow check symbol lines up with the dose pointer.

(See figure G).



Check the flow

Hold the pen with the needle pointing up.

Press and hold in the dose button until the dose counter returns to **0**. The **0** must line up with the dose pointer.

A drop of Wegovy® should appear at the needle tip. This drop indicates that your pen is ready for use.

If a drop does not appear, check the flow again. **This should only be done twice.**

If there is still no drop, **change the needle and check the flow once more.**

Do not use the pen if a drop of Wegovy® still does not appear.

(See figure H).



2 Set your dose

Turn the dose selector until the **dose counter stops**, and it **shows your prescribed dose**.


(See figure I).



The dashed line () in the dose counter will guide you to your dose.

The dose selector clicks differently when turned forward, backwards or past your dose. You will hear a 'click' every time you turn the dose selector. Do not set the dose by counting the number of clicks you hear.


(See figure J).



When your prescribed dose lines up with the dose pointer, you have selected your dose. In this picture, the dose **0.25 mg** is shown as an example.

If the dose counter stops before you reach your prescribed dose, see the section '**Do you have enough Wegovy®?**' below these instructions.


(See figure K).



Choose your injection site

Choose your upper arms, upper legs or stomach (keep a 5 cm distance from your belly button).

You may inject in the same body area each week, but make sure it is not in the same spot as used the last time.




3 Inject your dose

Insert the needle into your skin.

Make sure you can see the dose counter. Do not cover it with your fingers. This could interrupt the injection.

(See figure L).





Press and hold down the dose button until the dose counter shows 0.

(See figure M).

Keep pressing the dose button with the needle in your skin and slowly count to 6. The 0 must line up with the dose pointer. You may hear or feel a click when the dose counter returns to 0.

(See figure N).




Remove the needle from your skin. If the needle is removed earlier, a stream of Wegovy® may come from the needle tip and the full dose will not be delivered.

If blood appears at the injection site, press lightly on the area to stop the bleeding.

You may see a drop of Wegovy® at the needle tip after injecting. This is normal and does not affect your dose.

(See figure O).




4 After your injection

Lead the needle tip into the outer needle cap on a flat surface without touching the needle or the outer needle cap.

Once the needle is covered, carefully push the outer needle cap completely on.

(See figure P).




Unscrew the needle and dispose of it carefully as instructed by your doctor, nurse, pharmacist or local authorities.

Never try to put the inner needle cap back on the needle. You may stick yourself with the needle.

Always dispose of the needle immediately after each injection to prevent blocked needles, contamination, infection, and inaccurate dosing. **Never store your pen with the needle attached.**

(See figure Q).




<p>Put the pen cap on your pen after each use to protect Wegovy® from light.</p> <p>(See figure R).</p>	
<p>When the pen is empty, dispose of the pen without a needle on as instructed by your doctor, nurse, pharmacist, or local authorities.</p> <p>The pen cap and the empty carton can be disposed of in your household waste.</p>	
<p>About your needles</p>	
<p>How to identify a blocked or damaged needle</p> <ul style="list-style-type: none"> • If 0 does not appear in the dose counter after continuously pressing the dose button, you may have used a blocked or damaged needle. • In this case, you have not received any Wegovy® – even though the dose counter has moved from the original dose that you have set. <p>How to handle a blocked needle</p> <ul style="list-style-type: none"> • Change the needle as instructed in ‘1 Prepare your pen with a new needle’ and go to ‘2 Set your dose’. 	
<p>Caring for your pen</p>	

Treat your pen with care. Rough handling or misuse may cause inaccurate dosing. If this happens, you might not get the intended effect of Wegovy®.

- See the back of this leaflet to read the storage conditions for your pen.
- **Do not inject Wegovy® that has been exposed to direct sunlight.**
- **Do not subject Wegovy® to frost and never inject Wegovy® that has been frozen.** Dispose of the pen.
- **Do not drop your pen** or knock it against hard surfaces.
- **Do not try to refill your pen.** Once empty, it must be disposed of.
- **Do not try to repair your pen** or pull it apart.
- **Do not expose your pen to dust, dirt or liquid.**
- **Do not wash, soak or lubricate your pen.** If necessary, clean it with a mild detergent on a moistened cloth.

Do you have enough Wegovy®?

If the dose counter stops before you reach your prescribed dose, there is not enough Wegovy® left for a full dose. Dispose of the pen and use a new Wegovy® pen.



Important information

- **Only inject one dose of Wegovy® once weekly.** If you do not use your Wegovy® as prescribed, you may not get the intended effect of this medicine.
- If you use more than one type of injectable medicine, it is very **important to check the name and dose** of your pen label **before use**.
- **Do not use this pen without help if you have poor eyesight and cannot follow these instructions.** Get help from a person with good eyesight who is trained to use the Wegovy® pen.
- Always keep pen and needles **out of sight and reach of others, especially children.**
- **Never share** your pen or your needles with other people.
- **Needles are for single use only. Never reuse your needles** as it may lead to blocked needles, contamination, infection and inaccurate dosing.
- Caregivers must **be very careful when handling used needles** to prevent accidental needle stick injuries and infection.

Brosur kemasan: Informasi untuk pasien

Wegovy® 0,25 mg/dosis FlexTouch® larutan injeksi dalam pena yang sudah terisi (0,68 mg/mL)

Wegovy® 0,5 mg/dosis FlexTouch® larutan injeksi dalam pena yang sudah terisi (1,34 mg/mL)

Wegovy® 1 mg/dosis FlexTouch® larutan injeksi dalam pena yang sudah terisi (1,34 mg/mL)

Wegovy® 1,7 mg/dosis FlexTouch® larutan injeksi dalam pena yang sudah terisi (2,27 mg/mL)

Wegovy® 2,4 mg/dosis FlexTouch® larutan injeksi dalam pena yang sudah terisi (3,2 mg/mL)

semaglutide

Bacalah seluruh bagian brosur ini dengan teliti sebelum Anda mulai menggunakan obat ini karena brosur ini berisi informasi yang penting untuk Anda.

- Simpan brosur ini. Anda mungkin perlu membacanya kembali.
- Jika Anda memiliki pertanyaan lebih lanjut, tanyakan kepada dokter, apoteker atau perawat Anda.
- Obat ini telah diresepkan hanya untuk Anda. Jangan memberikannya kepada orang lain. Obat ini mungkin membahayakan mereka, meskipun jika mereka memiliki tanda-tanda sakit yang sama dengan Anda.
- Jika Anda mengalami efek samping apapun, bicarakan dengan dokter, apoteker atau perawat Anda. Termasuk kemungkinan efek samping apapun yang tidak tercantum dalam brosur ini. Lihat bagian 4.

Apa yang terdapat dalam brosur ini

1. Apa itu Wegovy® dan untuk apa kegunaannya
2. Apa yang Anda perlu ketahui sebelum Anda menggunakan Wegovy®
3. Bagaimana cara menggunakan Wegovy®
4. Efek samping yang mungkin dirasakan
5. Bagaimana cara menyimpan Wegovy®
6. Isi kemasan dan informasi lainnya

1. Apa itu Wegovy® dan untuk apa kegunaannya

Apa itu Wegovy®

Wegovy® adalah obat untuk menurunkan berat badan dan menjaga berat badan yang mengandung zat aktif semaglutide 0,68 mg/mL (0,25 mg/dosis); 1,34 mg/mL (0,5 mg/dosis dan 1 mg/dosis); 2,27 mg/mL (1,7 mg/dosis) dan 3,2 mg/mL (2,4 mg/dosis). Semaglutide serupa dengan hormon alami yang disebut *glucagon-like peptide-1* (GLP-1) yang dilepaskan dari usus setelah makan. Semaglutide bekerja di target (reseptor) di otak yang mengendalikan nafsu makan Anda, menyebabkan Anda merasa lebih kenyang dan berkurangnya rasa lapar dan mengalami berkurangnya keinginan terhadap makanan. Hal tersebut akan membantu Anda makan lebih sedikit makanan dan mengurangi berat badan Anda. Wegovy® juga dapat membantu mencegah penyakit jantung.

Untuk apa kegunaan Wegovy®

Wegovy® digunakan bersama dengan diet dan aktivitas fisik untuk menurunkan berat badan dan membantu berat badan tetap terkendali. Obat ini digunakan pada orang dewasa yang memiliki

- IMT 30 kg/m² atau lebih (obesitas) atau
- IMT setidaknya 27 kg/m² tetapi kurang dari 30 kg/m² (kelebihan berat badan) yang memiliki gangguan kesehatan terkait berat badan (seperti diabetes, tekanan darah tinggi, kadar lemak yang abnormal dalam darah, gangguan pernapasan ketika tidur yang disebut '*obstructive sleep apnea*' atau riwayat serangan jantung, stroke atau gangguan pembuluh darah).

IMT (Indeks Massa Tubuh) adalah pengukuran berat badan Anda yang berhubungan dengan tinggi badan Anda.

Wegovy® digunakan bersama dengan diet dan aktivitas fisik untuk manajemen berat badan pada remaja usia 12 tahun dan ke atas, yang memiliki

- obesitas **dan**
- berat badan > 60 kg.

Sebagai pasien remaja, Anda seharusnya hanya melanjutkan menggunakan Wegovy® jika Anda telah menurunkan setidaknya 5% dari IMT Anda setelah 12 minggu dengan dosis 2,4 mg atau dosis maksimum yang bisa ditoleransi (lihat bagian 3). Konsultasikan dengan dokter Anda sebelum Anda melanjutkan pengobatan.

Pengurangan risiko gangguan jantung yang serius pada orang dewasa

Wegovy® digunakan untuk mengurangi risiko gangguan jantung yang serius (kematian terkait jantung, serangan jantung, stroke) pada orang dewasa dengan riwayat penyakit jantung (seperti serangan jantung, stroke atau aliran darah yang buruk ke anggota badan) dan IMT ≥ 27 kg/m².

Pembatasan penggunaan

Wegovy® mengandung semaglutide dan seharusnya tidak digunakan dengan produk lain yang mengandung semaglutide atau agonis reseptor GLP-1 lainnya.

Keamanan dan khasiat Wegovy® yang dikombinasikan dengan produk lain untuk menurunkan berat badan, termasuk obat dengan resep dokter, obat bebas atau produk herbal belum diketahui.

Wegovy® belum diteliti pada pasien dengan riwayat pankreatitis (lihat bagian 2).

Remaja (≥ 12 tahun)

Keamanan dan khasiat semaglutide pada remaja prepubertal (Tanner tahap 1) belum diteliti.

2. Apa yang Anda perlu ketahui sebelum Anda menggunakan Wegovy®

Jangan menggunakan Wegovy®

- jika Anda alergi terhadap semaglutide atau zat lainnya dalam obat ini (tercantum di bagian 6).

Peringatan dan pencegahan

Bicarakan dengan dokter, apoteker atau perawat Anda sebelum menggunakan Wegovy®.

Penggunaan Wegovy® tidak direkomendasikan jika Anda:

- menggunakan produk lainnya untuk menurunkan berat badan,
- memiliki diabetes tipe 1,
- memiliki penurunan fungsi ginjal yang parah,
- memiliki penurunan fungsi hati yang parah,
- memiliki gagal jantung yang parah,
- memiliki penyakit mata diabetik (retinopati).

Terdapat sedikit pengalaman dengan Wegovy® pada pasien:

- usia 85 tahun dan ke atas,
- dengan gangguan hati,
- dengan gangguan perut atau usus yang parah sehingga mengakibatkan pengosongan lambung yang tertunda (disebut gastroparesis), atau jika Anda memiliki penyakit radang usus.

Konsultasikan dengan dokter Anda jika salah satu hal di atas terjadi pada Anda.

Jika Anda mengetahui bahwa Anda akan menjalani operasi dimana Anda akan dibius anestesi (tertidur), beritahu dokter Anda bahwa Anda sedang mengonsumsi Wegovy®.

- **Dehidrasi**
Selama pengobatan dengan Wegovy®, Anda mungkin merasa mual atau muntah, atau mengalami diare. Efek samping tersebut dapat menyebabkan dehidrasi (kehilangan cairan). Penting untuk Anda minum air yang cukup untuk mencegah dehidrasi. Hal tersebut sangat penting khususnya jika Anda memiliki gangguan ginjal. Bicarakan dengan dokter Anda jika Anda memiliki pertanyaan atau pertimbangan apapun.
- **Peradangan pankreas**
Jika Anda mengalami rasa nyeri yang parah dan terus-menerus di area perut (lihat bagian 4) – segera ke dokter karena hal tersebut dapat menjadi tanda pankreas yang meradang (pankreatitis akut).
- **Orang dengan diabetes tipe 2**
Wegovy® tidak dapat digunakan sebagai pengganti insulin. Jangan menggunakan Wegovy® sebagai kombinasi dengan obat lainnya yang mengandung agonis reseptor GLP-1 (seperti liraglutide, dulaglutide, exenatide atau lixisenatide).
- **Kadar gula darah yang rendah (hipoglikemia)**
Mengonsumsi sulfonilurea atau insulin dengan Wegovy® mungkin meningkatkan risiko kadar gula darah yang rendah (hipoglikemia). Lihat bagian 4 untuk tanda-tanda peringatan kadar gula darah yang rendah. Dokter Anda mungkin meminta Anda untuk memeriksa kadar gula darah Anda. Hal tersebut akan membantu dokter Anda

memutuskan apakah dosis sulfonilurea atau insulin perlu diubah untuk mengurangi risiko kadar gula darah yang rendah.

- **Penyakit mata diabetik (retinopati)**

Jika Anda memiliki penyakit mata diabetik dan sedang menggunakan insulin, obat ini mungkin menyebabkan memburuknya penglihatan Anda, dan hal tersebut mungkin memerlukan pengobatan. Peningkatan yang cepat dalam kontrol kadar gula darah mungkin menyebabkan memburuknya penyakit mata diabetik yang bersifat sementara. Jika Anda memiliki penyakit mata diabetik dan mengalami gangguan mata ketika mengonsumsi obat ini, bicarakan dengan dokter Anda.

Anak-anak dan remaja

Keamanan dan khasiat Wegovy® pada anak-anak di bawah usia 12 tahun dan remaja prepubertal belum diteliti dan tidak direkomendasikan untuk digunakan pada populasi ini.

Obat-obatan lain dan Wegovy®

Beritahu dokter, apoteker atau perawat Anda jika Anda sedang menggunakan, baru-baru ini menggunakan atau mungkin menggunakan obat-obatan lain apapun.

Beritahu dokter, apoteker atau perawat Anda khususnya jika Anda sedang menggunakan obat-obatan yang mengandung zat berikut ini:

- Warfarin atau obat-obatan yang serupa lainnya yang dikonsumsi melalui mulut untuk mengurangi pembekuan darah (antikoagulan oral). Ketika Anda memulai pengobatan misalnya dengan warfarin atau obat-obatan yang serupa, pemeriksaan darah yang sering untuk menentukan kemampuan darah Anda untuk membeku mungkin diperlukan.

Kehamilan dan menyusui

Obat ini seharusnya tidak digunakan selama kehamilan, karena belum diketahui apakah obat ini mungkin memengaruhi bayi Anda yang belum lahir. Oleh karena itu, direkomendasikan untuk menggunakan kontrasepsi ketika sedang menggunakan obat ini. Jika Anda ingin hamil, Anda seharusnya berhenti menggunakan obat ini setidaknya dua bulan sebelumnya. Jika Anda akan atau sedang hamil, berpikir Anda mungkin hamil atau berencana untuk memiliki bayi ketika sedang menggunakan obat ini, segera bicarakan dengan dokter Anda, karena pengobatan Anda akan perlu dihentikan.

Jangan menggunakan obat ini jika Anda sedang menyusui, karena belum diketahui apakah obat ini masuk ke dalam air susu ibu.

Mengemudi dan menggunakan mesin

Wegovy® tidak memengaruhi kemampuan Anda untuk mengemudi dan menggunakan mesin. Beberapa pasien mungkin merasa pusing ketika sedang menggunakan Wegovy® terutama selama 4 bulan pertama pengobatan (lihat bagian 4). Jika Anda merasa pusing, berhati-hatilah ketika sedang mengemudi atau menggunakan mesin. Jika Anda memerlukan informasi lebih lanjut, bicarakan dengan dokter, apoteker atau perawat Anda.

Orang dengan diabetes tipe 2

Jika Anda menggunakan obat ini sebagai kombinasi dengan sulfonilurea atau insulin, kadar gula darah yang rendah (hipoglikemia) mungkin terjadi yang mungkin mengurangi kemampuan Anda untuk berkonsentrasi. Hindari mengemudi atau menggunakan mesin jika Anda mengalami tanda-tanda kadar gula darah yang rendah. Lihat bagian 2, 'Peringatan dan pencegahan' untuk informasi tentang peningkatan risiko kadar gula darah yang rendah dan bagian 4 untuk tanda-tanda peringatan kadar gula darah yang rendah. Bicarakan dengan dokter Anda untuk informasi lebih lanjut.

Wegovy® mengandung natrium

Obat ini mengandung kurang dari 1 mmol natrium (23 mg) per dosis, yang pada dasarnya 'bebas natrium'.

3. Bagaimana cara menggunakan Wegovy®

Selalu gunakan obat ini seperti yang diberitahu oleh dokter Anda. Periksakan dengan dokter, apoteker atau perawat Anda jika Anda tidak yakin.

Berapa banyak yang digunakan

Dewasa

Dosis yang direkomendasikan adalah 2,4 mg seminggu sekali.

Pengobatan Anda akan dimulai dengan dosis rendah yang akan ditingkatkan secara bertahap selama 16 minggu pengobatan.

- Ketika Anda pertama kali mulai menggunakan Wegovy®, dosis awal adalah 0,25 mg seminggu sekali.
- Dokter Anda akan menginstruksikan Anda untuk menaikkan dosis Anda secara bertahap setiap 4 minggu hingga Anda mencapai dosis yang direkomendasikan 2,4 mg seminggu sekali.
- Ketika Anda mencapai dosis yang direkomendasikan 2,4 mg, jangan menaikkan dosis ini lebih lanjut.
- Jika Anda merasa sangat terganggu dengan mual atau muntah, bicarakan dengan dokter Anda tentang penundaan eskalasi dosis atau penurunan ke dosis sebelumnya hingga gejala membaik.

Biasanya, Anda akan diberitahu untuk mengikuti tabel di bawah ini.

Eskalasi dosis	Dosis mingguan
Minggu 1-4	0,25 mg
Minggu 5-8	0,5 mg
Minggu 9-12	1 mg
Minggu 13-16	1,7 mg
Sejak minggu 17	2,4 mg

Dokter Anda akan menilai pengobatan Anda secara teratur.

Remaja (12 tahun dan ke atas)



Untuk remaja, eskalasi dosis yang sama seperti pada orang dewasa seharusnya diterapkan. (lihat di atas). Dosis seharusnya ditingkatkan hingga 2,4 mg (dosis pemeliharaan) atau dosis maksimum yang bisa ditoleransi telah tercapai. Dosis mingguan yang lebih tinggi dari 2,4 mg tidak direkomendasikan.

Bagaimana Wegovy® diberikan

Wegovy® diberikan dengan menyuntikkan di bawah kulit (penyuntikan subkutan). Jangan menyuntikkannya ke dalam pembuluh darah atau otot.

- Tempat terbaik untuk menyuntikkan adalah bagian depan lengan atas, kaki bagian atas atau perut.
- Sebelum Anda menggunakan pena untuk pertama kalinya, dokter, apoteker atau perawat Anda akan menunjukkan bagaimana cara menggunakannya.

Instruksi rinci tentang bagaimana cara menggunakan pena tersedia di sisi sebaliknya dari brosur ini.

Orang dengan diabetes tipe 2

Beritahu dokter Anda jika Anda memiliki diabetes tipe 2. Dokter Anda mungkin menyesuaikan dosis obat diabetes Anda untuk mencegah Anda mengalami kadar gula darah yang rendah.

Data klinis terkait khasiat dan keamanan terbatas sampai 68 minggu.

Kapan menggunakan Wegovy®

- Anda seharusnya menggunakan obat ini seminggu sekali dan jika memungkinkan, di hari yang sama setiap minggunya.
- Anda dapat menyuntikkan kapan saja sepanjang hari – tidak bergantung pada makanan.

Jika perlu, Anda dapat mengubah hari penyuntikan mingguan obat ini selama setidaknya 3 hari sejak penyuntikan terakhir Anda. Setelah memilih hari pemberian dosis yang baru, lanjutkan dengan pemberian dosis seminggu sekali.

Jika Anda menggunakan Wegovy® lebih dari yang seharusnya

Bicarakan segera dengan dokter Anda. Anda mungkin mengalami efek samping seperti mual, muntah atau diare, yang mungkin menyebabkan dehidrasi (kehilangan cairan).

Jika Anda lupa menggunakan Wegovy®

Jika Anda lupa menyuntikkan dosis dan:

- sudah 5 hari atau kurang sejak Anda seharusnya menggunakan Wegovy®, segera gunakan ketika Anda ingat. Kemudian suntikkan dosis Anda selanjutnya seperti biasa di hari yang Anda jadwalkan.
- sudah lebih dari 5 hari sejak Anda seharusnya menggunakan Wegovy®, lewati dosis yang terlupa. Kemudian suntikkan dosis Anda selanjutnya seperti biasa di hari yang Anda jadwalkan selanjutnya.

Jangan menggunakan dosis ganda untuk mengganti dosis yang terlupa.

Jika Anda berhenti menggunakan Wegovy®

Jangan berhenti menggunakan obat ini tanpa berbicara dengan dokter Anda.

Jika Anda memiliki pertanyaan apapun lebih lanjut tentang penggunaan obat ini, tanyakan kepada dokter, apoteker atau perawat Anda.

4. Efek samping yang mungkin dirasakan

Sama seperti semua obat-obatan, obat ini dapat menyebabkan efek samping, meskipun tidak semua orang mengalami efek samping tersebut.

Efek samping yang serius

Umum (mungkin memengaruhi hingga 1 dari 10 orang)

- Komplikasi penyakit mata diabetik (retinopati diabetik). Jika Anda memiliki diabetes, Anda seharusnya menginformasikan dokter Anda jika Anda mengalami gangguan mata, seperti perubahan penglihatan, selama pengobatan dengan obat ini.

Tidak umum (mungkin memengaruhi hingga 1 dari 100 orang)

- Peradangan pankreas (pankreatitis akut). Tanda-tanda peradangan pankreas mungkin termasuk rasa nyeri yang parah dan bertahan lama di perut Anda, rasa nyeri mungkin berpindah ke punggung Anda. Anda seharusnya segera menemui dokter Anda jika Anda mengalami gejala tersebut.

Jarang (mungkin memengaruhi hingga 1 dari 1.000 orang)

- Reaksi alergi yang parah (reaksi anafilaksis, angioedema). Anda seharusnya segera mencari bantuan medis dan menginformasikan dokter Anda jika Anda mengalami gejala seperti kesulitan bernapas, pembengkakan, pusing, detak jantung yang cepat, berkeringat dan kehilangan kesadaran atau pembengkakan cepat di bawah kulit di area seperti wajah, tenggorokan, lengan dan kaki, yang dapat mengancam jiwa jika pembengkakan tenggorokan menghalangi jalan napas.

Tidak diketahui (frekuensi tidak bisa diperkirakan dari data yang tersedia)

- Penyumbatan pada usus yang ditandai dengan sembelit yang parah, nyeri lambung, kembung, muntah, dan lain-lain.

Efek samping lainnya

Sangat umum (mungkin memengaruhi 1 dari 10 orang)

- sakit kepala
- mual
- muntah
- diare
- konstipasi
- nyeri perut
- merasa lemah atau lelah

– hal tersebut terutama terlihat selama eskalasi dosis dan biasanya hilang seiring waktu.

Umum (mungkin memengaruhi hingga 1 dari 10 orang)

- merasa pusing
- sakit perut atau gangguan pencernaan
- sendawa
- kentut (flatulensi)
- perut kembung
- radang perut ('gastritis') – tanda-tandanya termasuk nyeri perut, mual atau muntah
- refluks atau rasa panas di perut – juga disebut 'penyakit refluks gastro-esofagus'
- batu empedu
- rambut rontok
- reaksi tempat penyuntikan
- perubahan dalam merasakan makanan atau minuman
- perubahan dalam sensasi kulit
- kadar gula darah yang rendah (hipoglikemia) pada pasien diabetes tipe 2.

Tanda-tanda peringatan kadar gula darah yang rendah mungkin datang tiba-tiba. Hal tersebut dapat mencakup: keringat dingin, kulit pucat dingin, sakit kepala, detak jantung yang cepat, mual atau sangat lapar, perubahan penglihatan, merasa mengantuk atau lemah, merasa gugup, cemas atau bingung, sulit berkonsentrasi atau gemetar.

Dokter Anda akan memberitahu Anda bagaimana cara mengobati kadar gula darah yang rendah dan apa yang dilakukan jika Anda melihat tanda-tanda peringatan ini.

Kadar gula darah yang rendah lebih mungkin terjadi jika Anda juga mengonsumsi sulfonilurea atau insulin. Dokter Anda mungkin mengurangi dosis obat-obatan tersebut sebelum Anda mulai menggunakan obat ini.

Tidak umum (mungkin memengaruhi hingga 1 dari 100 orang)

- tekanan darah rendah
- merasa pusing atau pening ketika berdiri atau duduk karena penurunan tekanan darah
- detak jantung yang cepat
- peningkatan enzim pankreas (seperti lipase dan amilase) yang ditunjukkan dalam pemeriksaan darah.
- penundaan pengosongan lambung

Pelaporan efek samping

Jika Anda mengalami efek samping apapun selama atau setelah penggunaan obat, bicarakan dengan dokter atau apoteker Anda. Termasuk kemungkinan efek samping apapun yang tidak tercantum dalam brosur ini. Anda juga dapat melaporkan efek samping tersebut secara langsung ke Novo Nordisk Indonesia melalui IDJKAgree@novonordisk.com. Dengan melaporkan efek samping, Anda dapat membantu menyediakan informasi lebih lanjut mengenai keamanan obat ini.

5. Bagaimana cara menyimpan Wegovy®

Jauhkan obat ini dari penglihatan dan jangkauan anak-anak.

Jangan menggunakan obat ini setelah tanggal kadaluwarsa yang tercantum di label pena dan karton setelah 'Expiry'. Tanggal kadaluwarsa merujuk di hari terakhir di bulan tersebut.

Sebelum dibuka

Simpan di lemari pendingin (2°C – 8°C). Jangan dibekukan. Jauhkan dari elemen pendingin. Lindungi dari cahaya.

Selama penggunaan

- Anda dapat menyimpan pena selama 6 minggu ketika disimpan di suhu di bawah 30°C atau di lemari pendingin (2°C – 8°C) jauh dari elemen pendingin. Jangan membekukan Wegovy® dan jangan menggunakannya jika telah dibekukan.
- Ketika Anda sedang tidak menggunakan pena, pasang tutup pena untuk melindungi dari cahaya.

Jangan menggunakan obat ini jika Anda melihat larutan tidak jernih dan tidak berwarna.

Jangan membuang obat-obatan apapun melalui saluran limbah air atau limbah rumah tangga. Tanyakan kepada apoteker Anda bagaimana cara membuang obat-obatan yang tidak digunakan lagi. Langkah-langkah tersebut akan membantu melindungi lingkungan.

6. Isi kemasan dan informasi lainnya

Apa yang terkandung dalam Wegovy®

- Zat aktifnya adalah semaglutide.

Wegovy® 0,25 mg/dosis FlexTouch® larutan injeksi

Setiap pena yang sudah terisi mengandung 1 mg semaglutide dalam 1,5 mL (0,68 mg/mL).

Wegovy® 0,5 mg/dosis FlexTouch® larutan injeksi

Setiap pena yang sudah terisi mengandung 2 mg semaglutide dalam 1,5 mL (1,34 mg/mL).

Wegovy® 1 mg/dosis FlexTouch® larutan injeksi

Setiap pena yang sudah terisi mengandung 4 mg semaglutide dalam 3 mL (1,34 mg/mL).

Wegovy® 1,7 mg/dosis FlexTouch® larutan injeksi

Setiap pena yang sudah terisi mengandung 6,8 mg semaglutide dalam 3 mL (2,27 mg/mL).

Wegovy® 2,4 mg/dosis FlexTouch® larutan injeksi

Setiap pena yang sudah terisi mengandung 9,6 mg semaglutide dalam 3 mL (3,2 mg/mL).

- Zat lainnya adalah dinatrium fosfat dihidrat, propilen glikol, fenol, asam hidroklorida/natrium hidroksida (untuk pengaturan pH), air untuk injeksi. Lihat juga bagian 2 'Wegovy® mengandung natrium' untuk informasi tentang natrium.

Seperti apa bentuk Wegovy® dan isi kemasan

Wegovy® adalah larutan injeksi yang jernih dan tidak berwarna atau hampir tidak berwarna dalam pena sekali pakai yang sudah terisi.

Setiap pena berisi 4 dosis.

Wegovy® 0,25; 0,5; 1; 1,7 dan 2,4 mg/dosis FlexTouch® larutan injeksi tersedia dalam kemasan berikut:

1 pena yang sudah terisi dan 4 jarum NovoFine® Plus sekali pakai.

HARUS DENGAN RESEP DOKTER

Reg. No.: DK12464605443A1 (0,25 mg/dosis; 0,68 mg/mL)

DK12464605443B1 (0,5 mg/dosis; 1,34 mg/mL)

DK12464605443B1 (1 mg/dosis; 1,34 mg/mL)

DK12464605443C1 (1,7 mg/dosis; 2,27 mg/mL)

DK12464605443D1 (2,4 mg/dosis; 3,2 mg/mL)

Diproduksi oleh:

Novo Nordisk A/S
Brennum Park
DK-3400 Hillerød
Denmark

Dirilis oleh:

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark

Didaftarkan oleh:

PT Beta Pharmacon
Karawang – Indonesia

Didistribusikan oleh:

PT Anugrah Argon Medica
Indonesia

Berdasarkan persetujuan tanggal:

Wegovy®, NovoFine® dan NovoTwist® adalah merek dagang yang dimiliki oleh Novo Nordisk A/S, Denmark

© 2025

Novo Nordisk A/S

Informasi halaman depan:

EN MAY 2025

Page 10 of 22



Wegovy®

0,25 mg/dosis; 0,5 mg/dosis

1 mg/dosis, 1,7 mg/dosis

2,4 mg/dosis

FlexTouch®

semaglutide

Instruksi bagaimana cara menggunakan Wegovy®

Sebelum Anda mulai menggunakan pena Wegovy® FlexTouch® seminggu sekali Anda, **selalu baca instruksi ini dengan teliti**, dan bicarakan dengan dokter, perawat atau apoteker Anda tentang bagaimana cara menyuntikkan Wegovy® dengan benar.

Pena Wegovy® adalah pena yang sudah terisi dengan dosis yang **berisi empat dosis Wegovy® yang diresepkan untuk Anda, sesuai dengan empat kali penggunaan seminggu sekali**.

Gunakan tabel di karton untuk melacak berapa banyak penyuntikan yang telah Anda gunakan dan berapa banyak dosis yang tersisa di pena Anda.

Wegovy® tersedia dalam lima pena yang berbeda, masing-masing berisi salah satu dari dosis semaglutide yang diresepkan berikut ini:

0.25 mg

0.5 mg

1 mg

1.7 mg

2.4 mg

Selalu mulai dengan memeriksa label pena Anda untuk memastikan pena berisi dosis Wegovy® yang diresepkan untuk Anda.

Pena Anda dirancang untuk digunakan dengan jarum sekali pakai NovoFine® Plus, NovoFine® atau NovoTwist® hingga panjang 8 mm.


Kemasan berisi:

- Pena Wegovy®
- 4 jarum NovoFine® Plus
- Brosur kemasan

Pena Wegovy® FlexTouch® (contoh)

Catatan: Pena Anda mungkin berbeda ukuran dan label pena Anda mungkin berbeda warna dari contoh ditunjukkan di gambar.

Instruksi ini berlaku untuk semua pena Wegovy® FlexTouch®.



Jarum NovoFine® Plus (contoh)




1 Mempersiapkan pena Anda dengan jarum baru

Periksa nama dan dosis pena Anda untuk memastikan pena berisi dosis Wegovy® yang diresepkan untuk Anda.

Cabut tutup pena.


(Lihat gambar A).



Periksa larutan di pena Anda jernih dan tidak berwarna.

Lihat melalui jendela pena. Jika Wegovy® terlihat keruh atau berwarna, jangan menggunakan pena.

(Lihat gambar B).






Selalu gunakan jarum baru untuk setiap penyuntikan.


Ambil jarum ketika Anda siap untuk melakukan penyuntikan Anda. Periksa label kertas dan tutup jarum bagian luar dari kerusakan yang bisa memengaruhi sterilitas. Jika ada kerusakan apapun yang terlihat, gunakan jarum baru.

Lepaskan label kertas.

(Lihat gambar C).



<p>Dorong jarum lurus ke pena. Putar hingga kencang.</p> <p>(Lihat gambar D).</p>	
<p>Jarum ditutupi oleh dua tutup. Anda harus melepaskan keduanya.</p> <p>Jika Anda lupa melepaskan kedua tutup, Anda tidak akan menyuntikkan Wegovy® apapun.</p> <p>Cabut tutup jarum bagian luar dan simpan untuk nanti. Anda akan memerlukannya untuk melepaskan jarum dari pena dengan aman setelah penyuntikan.</p> <p>Cabut tutup jarum bagian dalam dan buang. Setetes Wegovy® mungkin muncul di ujung jarum. Anda tetap harus memeriksa aliran Wegovy® jika Anda menggunakan pena baru untuk pertama kalinya. Lihat 'Periksa aliran dengan setiap pena baru'.</p> <p>Jangan menggunakan jarum yang bengkok atau rusak. Untuk informasi lebih lanjut tentang penanganan jarum, lihat 'Tentang jarum Anda' di bagian bawah instruksi ini.</p> <p>(Lihat gambar E).</p>	

Periksa aliran dengan setiap pena baru	
<p>Jika pena Wegovy® Anda sudah digunakan, lihat '2 Mengatur dosis Anda'.</p> <p>Hanya periksa aliran Wegovy® sebelum penyuntikan pertama Anda dengan setiap pena baru.</p> <p>Putar pemilih dosis hingga Anda melihat simbol pemeriksa aliran (•• —).</p> <p>(Lihat gambar F).</p>	
<p>Pastikan simbol pemeriksa aliran sejajar dengan penunjuk dosis.</p> <p>(Lihat gambar G).</p>	

Periksa alirannya

Pegang pena dengan jarum mengarah ke atas.

Tekan dan tahan tombol dosis hingga penghitung dosis kembali ke **0**. Tanda **0** harus sejajar dengan penunjuk dosis.

Setetes Wegovy® seharusnya muncul di ujung jarum. Tetesan tersebut menunjukkan bahwa pena Anda siap digunakan.

Jika tetesan tidak muncul, periksa kembali alirannya. **Hal tersebut seharusnya hanya boleh dilakukan dua kali.**

Jika tetesan tetap tidak muncul, **ganti jarum dan periksa alirannya sekali lagi.**

Jangan menggunakan pena jika tetesan Wegovy® tetap tidak muncul.


(Lihat gambar H).



2 Mengatur dosis Anda

Putar pemilih dosis hingga **penghitung dosis berhenti**, dan penghitung dosis **menunjukkan dosis yang diresepkan untuk Anda**.


(Lihat gambar I).



Garis putus-putus (ⓘ) di penghitung dosis akan memandu Anda ke dosis Anda.

Pemilih dosis berbunyi klik secara berbeda ketika diputar ke depan, ke belakang atau melewati dosis Anda. Anda akan mendengar 'klik' setiap kali Anda memutar pemilih dosis. Jangan mengatur dosis dengan menghitung jumlah klik yang Anda dengar.


(Lihat gambar J).



Ketika dosis yang diresepkan untuk Anda sejajar dengan penunjuk dosis, Anda telah memilih dosis Anda. Di gambar ini, dosis **0.25 mg** ditunjukkan sebagai contoh.

Jika penghitung dosis berhenti sebelum Anda mencapai dosis yang diresepkan untuk Anda, lihat bagian '**Apakah Anda memiliki Wegovy® yang cukup?**' di bagian bawah instruksi ini.


(Lihat gambar K).



Pilih lokasi penyuntikan Anda

Pilih lengan bagian atas, kaki bagian atas atau perut Anda (beri jarak 5 cm dari pusar Anda).

Anda mungkin menyuntikkan di area tubuh yang sama setiap minggu, tetapi pastikan tidak di titik yang sama yang digunakan di penyuntikan sebelumnya




3 Menyuntikkan dosis Anda

Masukkan jarum ke dalam kulit Anda.

Pastikan Anda dapat melihat penghitung dosis. Jangan menutupi penghitung dosis dengan jari Anda. Hal tersebut dapat mengganggu penyuntikan.

(Lihat gambar L).




Tekan dan tahan tombol dosis hingga penghitung dosis menunjukkan -0-.

(Lihat gambar M).

Tetap tekan tombol dosis dengan jarum di dalam kulit Anda dan hitung perlahan hingga 6. Tanda -0- harus sejajar dengan penunjuk dosis. Anda mungkin mendengar atau merasakan bunyi klik ketika penghitung dosis kembali ke -0-.

(Lihat gambar N).




Lepaskan jarum dari kulit Anda. Jika jarum dilepaskan lebih awal, aliran Wegovy® mungkin keluar dari ujung jarum dan dosis penuh tidak diberikan.

Jika darah muncul di lokasi penyuntikan, tekan ringan di area tersebut untuk menghentikan pendarahan.

Anda mungkin melihat setetes Wegovy® di ujung jarum setelah penyuntikan. Hal tersebut normal dan tidak memengaruhi dosis Anda.

(Lihat gambar O).




4 Setelah penyuntikan Anda

Arahkan ujung jarum ke tutup jarum bagian luar di permukaan yang rata tanpa menyentuh jarum atau tutup jarum bagian luar.

Setelah jarum tertutup, dorong tutup jarum bagian luar dengan hati-hati.

(Lihat gambar P).




Lepaskan jarum dan buang dengan hati-hati seperti yang diinstruksikan oleh dokter, perawat, apoteker atau otoritas setempat Anda.

Jangan mencoba memasang kembali tutup jarum bagian dalam ke jarum. Anda mungkin tertusuk jarum.

Selalu buang jarum segera setelah setiap penyuntikan untuk mencegah jarum tersumbat, kontaminasi, infeksi dan dosis yang tidak akurat. **Jangan menyimpan pena Anda dengan jarum terpasang.**

(Lihat gambar Q).



Pasang tutup pena di pena Anda setelah setiap penggunaan untuk melindungi Wegovy® dari cahaya.

(Lihat gambar R).



Ketika pena habis, buang pena tanpa jarum seperti yang diinstruksikan oleh dokter, perawat, apoteker atau otoritas setempat Anda.

Tutup pena dan karton kosong dapat dibuang ke limbah rumah tangga Anda.

Tentang jarum Anda

Bagaimana cara mengidentifikasi jarum yang tersumbat atau rusak

- Jika tanda **0** tidak muncul di penghitung dosis setelah terus menerus menekan tombol dosis, Anda mungkin telah menggunakan jarum yang tersumbat atau rusak.
- Dalam hal tersebut, Anda **belum** menerima Wegovy® sama sekali – meskipun penghitung dosis telah berpindah dari dosis awal yang telah Anda atur.

Bagaimana cara menangani jarum yang tersumbat

- Ganti jarum seperti yang diinstruksikan di '**1 Mempersiapkan pena Anda dengan jarum baru**' dan '**2 Mengatur dosis Anda**'.

Pemeliharaan pena Anda


Perlakukan pena Anda dengan hati-hati. Penanganan yang kasar atau penyalahgunaan

mungkin menyebabkan dosis yang tidak akurat. Jika hal tersebut terjadi, Anda mungkin tidak mendapatkan efek yang diinginkan dari Wegovy®.

- Lihat bagian belakang brosur ini untuk membaca kondisi penyimpanan pena Anda.
- **Jangan menyuntikkan Wegovy® yang telah terkena sinar matahari langsung.**
- **Jangan membekukan Wegovy® dan jangan menyuntikkan Wegovy® yang telah dibekukan.** Buang pena.
- **Jangan menjatuhkan pena Anda** atau membenturkannya ke permukaan yang keras.
- **Jangan mencoba untuk mengisi ulang pena Anda.** Ketika habis, pena harus dibuang.
- **Jangan mencoba untuk memperbaiki pena Anda** atau memisahkan komponen-komponennya.
- **Jangan membiarkan pena Anda terkena debu, kotoran atau cairan.**
- **Jangan mencuci, merendam atau melumasi pena Anda.** Jika perlu, bersihkan pena dengan deterjen ringan di kain yang lembab.

Apakah Anda memiliki Wegovy® yang cukup?

Jika penghitung dosis berhenti sebelum Anda mencapai dosis yang diresepkan untuk Anda, tidak ada Wegovy® yang tersisa yang cukup untuk dosis penuh. Buang pena dan gunakan pena Wegovy® baru.



Informasi penting

- **Hanya menyuntikkan satu dosis Wegovy® seminggu sekali.** Jika Anda tidak menggunakan Wegovy® sesuai yang diresepkan, Anda mungkin tidak mendapatkan efek yang diinginkan dari obat ini.
- Jika Anda menggunakan lebih dari satu jenis obat suntik, **sangat penting untuk memeriksa nama dan dosis di label pena Anda sebelum digunakan.**
- **Jangan menggunakan pena ini tanpa bantuan jika Anda memiliki penglihatan yang buruk dan tidak dapat mengikuti instruksi ini.** Dapatkan bantuan dari orang dengan penglihatan yang baik yang terlatih untuk menggunakan pena Wegovy®.
- Selalu jauhkan pena dan jarum **dari pandangan dan jangkauan orang lain, khususnya anak-anak.**
- **Jangan berbagi** pena atau jarum Anda dengan orang lain.
- **Jarum hanya untuk sekali pakai. Jangan menggunakan kembali jarum Anda** karena mungkin menyebabkan jarum tersumbat, kontaminasi, infeksi dan dosis yang tidak akurat.
- Perawat harus **sangat berhati-hati ketika menangani jarum yang telah dipakai** untuk mencegah cedera karena tidak sengaja tertusuk jarum dan infeksi.